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1. INTRODUCTION 
(1, 2)
 
Oral routes of drug administration have wide acceptance up to 50-60% of total 
dosage forms. Solid dosage forms are popular because of ease of administration, accurate 
dosage, self-medication, pain avoidance and most importantly the patient compliance. The 
most popular solid dosage forms are being tablets and capsules; one important drawback 
of this dosage forms for some patients, is the difficulty to swallow. Drinking water plays 
an important role in the swallowing of oral dosage forms. Often times people experience 
inconvenience in swallowing conventional dosage forms such as tablet when water is not 
available, in the case of the motion sickness (kinetosis) and sudden episodes of coughing 
during the common cold, allergic condition and bronchitis. For these reason, tablets that 
can rapidly dissolve or disintegrate in the oral cavity have attracted a great deal of 
attention. Fast dissolving tablets (FDT) are not only indicated for people who have 
swallowing difficulties, but also are ideal for active people. 
FDT are also called as mouth-dissolving tablets, melt-in mouth tablets, 
Orodispersible tablets, rapimelts, porous tablets, quick dissolving etc. FDT are those when 
put on tongue disintegrate instantaneously releasing the drug which dissolve or disperses 
in the saliva. The faster the drug into solution, quicker the absorption and onset of clinical 
effect. Some drugs are absorbed from the mouth, pharynx and esophagus as the saliva 
passes down into the stomach. In such cases, bioavailability of drug is significantly 
greater than those observed from conventional tablets dosage form. The advantage of fast 
dissolving dosage forms are increasingly being recognized in both, industry and 
academics.  
According to European pharmacopoeia, the FDT should disperse/disintegrate in 
less than three minutes. The basic approach in development of FDT is the use of 
superdisintegrants like cross linked carboxymethyl cellulose (croscarmellose), sodium 
starch glycolate (primogel, explotab), polyvinylpyrollidone (polyplasdone) etc, which 
provide instantaneous disintegration of tablet after putting on tongue, their by release the 
drug in saliva. 
The bioavailability of some drugs may be increased due to absorption of drug in 
oral cavity and also due to pregastric absorption of saliva containing dispersed drugs that 
pass down into the stomach. More ever, the amount of drug that is subjected to first pass 
metabolism is reduced as compared to standard tablet. The technologies used for 
manufacturing FDTs are freeze-drying, spray-drying, tablet moulding, sublimation, sugar-
based excipients, tablet compression, and disintegration addition. As a result of increased 
life expectancy, the elderly constitute a large portion of the worldwide population today. 
These people eventually will experience deterioration of their physiological and physical 
abilities. 
Recent developments in technology have presented viable alternatives for the 
patients who may have difficulty in swallowing tablets or liquids.  
To overcome these drawbacks, FDT or orally disintegrating tablets (ODT) has 
emerged as alternative oral dosage forms. These are novel types, of tablets that 
disintegrate/dissolve/disperse in saliva within few seconds. 
 
1.1 TABLETS 
3
: 
Tablets may be defined as solid pharmaceutical dosage forms containing 
medicament or medicaments with or without suitable recipients & prepared either by 
compression or molding. 
1.1.1 Advantages of tablets:
  
Some of the potential advantages of tablets are as follows.
 
 They are the unit dosage form having greatest capabilities amongst all the oral dosage 
form for the dose precision and least content variability. 
 Their cost is lowest amongst all the oral dosage forms. 
 They are easiest and cheapest for packaging and transportation. 
 Tablets are better suited to large-scale production than other unit oral dosage forms. 
 They lend themselves to certain special release profile products such as enteric or 
delayed release products. 
 They have the best-combined properties of chemical, mechanical, microbiological 
stability amongst all the oral dosage forms. 
 
 
1.1.2 Classification of tablets:
 
Based on the route of administration or the function, the tablets are classified as follows.
 
i) Tablets ingested orally: 
 Compressed tablet 
 Multiple compressed tablet              
a) Layered Tablet 
b) Compression coated Tablet 
 Repeat action Tablet 
 Delayed action and enteric-coated Tablet 
 Sugar and chocolate-coated tablet 
a) Film coated tablet 
b) Chewable Tablet 
ii) Tablets used in the oral cavity: 
 Buccal Tablet 
 Sublingual Tablet 
 Troches and Lozenges 
 Dental cones 
iii) Tablets administered by other routes: 
 Implantation Tablet 
 Vaginal Tablets 
vi) Tablets used to prepare solution: 
 Effervescent Tablet 
 Dispensing Tablet 
 Hypodermic Tablet 
 Tablets Triturates  
 
 
 
 
 
1.1.3 Manufacturing Methods
 3
: 
Tablets are manufactured by Wet granulation, Dry granulation or direct 
compression method. 
i) Wet Granulation: 
Wet granulation is the process in which a wet mass of powder is formed by 
addition of liquid in a vessel equipped with any type of agitation that will produce 
agglomeration or granules. These granules after drying are compressed to form tablets.  
ii) Dry Granulation: 
In this technique, there is no use of liquids. The process involves the formation of 
slugs. Then the slugs are screened or milled to produce granules. The granules formed are 
then compressed to form tablets.  
 
iii) Direct Compression: 
The term direct compression is used to define the process by which tablets are 
compressed directly from powder blends of active ingredient and suitable excipients, 
which will flow uniformly in the die cavity & forms a firm compact.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table No.1.1 Processing steps commonly required in the various tablet 
granulation preparation techniques 
Processing 
steps 
Wet 
Granulation 
Dry 
Granulation 
Direct 
Compression 
Raw materials       
Weight       
Screen       
Mix         - 
Compress (slug)                  -       - 
Wet mass        -     - 
Mill        -     - 
Dry        -     - 
Mill         - 
Mix         - 
Compress       
 
1.1.4 Advantages of Dry Method: 
 This process is more economical. It requires fewer manufacturing steps, less 
processing time & thus reduces labour cost & less process validation. 
 The processing steps required no need of moisture, heat, and high compaction 
pressure. 
 There is an optimization of tablet disintegration, in which each primary drug 
particle is liberated from the tablet mass & is available for dissolution. 
 Disintegrating agents like starch are more effective when processed by dry 
granulation compression than wet granulation technique 
                 
In the present aging society, easy-to-use dosage forms for elderly patient, whose 
swallowing function is often decreased, are in great demand. The use of conventional 
tablets, capsules, and liquid or syrup preparations were not always easy-to-use dosage 
forms for elderly patients because of their decrease motor function. Similarly   the use of 
conventional tablets is challenging to paediatric, geriatric, and uncooperative patients who 
may have difficulty to swallow tablets and is also problematic when water is unavailable 
or when patients have a persistent cough or gag-reflux. 
These problems have been addressed by the recent introduction of FDT which also 
known as quick-dissolving tablet (also known as fast-dissolving multiparticulate, rapid-
dissolving, mouth-dissolving, fast-melting, orodispersing tablets) is an oral dosage form 
that does not require water for swallowing. The tablets dissolve within 60 seconds when 
placed in mouth or in oral cavity. 
 1.2 FAST DISSOLVING TABLETS (FDT) 
4
: 
In recent decades, a variety of pharmaceutical research has been conducted to 
develop new dosage forms. Considering quality of life, most of these efforts have been 
focused on ease of medication. Among the dosage form developed to facilitate ease of 
medication, the rapid disintegrating tablet is one of the most widely employed commercial 
products. 
1.2.1 Definition: 
A fast-dissolving drug delivery system in most cases is a tablet that dissolving or 
disintegrates in the oral cavity without the need of water or chewing. Most fast-dissolving 
drug delivery system films must include substances to mask the taste of the active 
ingredient. This masked active ingredient is then swallowed by the patients saliva along 
with the soluble and insoluble excipients. 
These are also called melt-in-mouth, repimelt, porous tablet, oro-dipersible, quick 
dissolving or rapid disintegrating tablets. FDTs are also called as Oro-dispersible tablets, 
Quick disintegrating tablets, Oral Disintegrating tablets, rapid dissolving tablets, Porous 
tablets and Rapimelts.  
Recently, European Pharmacopoeia has used the term FDT that disperses readily 
and within 3 min in mouth before swallowing. 
United State Food and Drug Administration (FDA) defined FDT as, ―A solid 
dosage form containing medicinal substance of active ingredient which disintegrates 
usually within a matter of seconds.‖ 
“FDT are solid dosage form that contains medicinal substances and that 
disintegrate and dissolve rapidly without water (within seconds).‖ 
The need for delivering drugs to patients efficiently and with few side effects has 
prompted pharmaceutical companies to engage in the development of new drug delivery 
systems. A solid dosage form that dissolves or disintegrates rapidly in oral   cavity, 
resulting in solution or suspension without the need of water is known as fast dissolving 
dosage form or oral dissolving tablets. When this type of tablet is gone into the stomach, 
the 0.1N HCL will serve to rapidly dissolve the tablet. 
Many patients find it difficult to swallow tablets and hard gelatin capsules and do 
not take their medicines as prescribed. Target populations for these new fast 
dissolving/disintegrating dosage forms have generally been paediatric, geriatric, bedridden 
or developmentally disabled patients., who are travelling or who have little or no access of 
water are also good candidates for fast dissolving / disintegrating tablets. Other groups 
that may experience problems using conventional oral dosage form include the mentally 
ill, developmentally disable and patients who are uncooperative. A difficulty in 
swallowing (dysphasia) tablets or capsules is common problem among all age groups, 
especially in elderly and paediatrics. For this reasons, tablets that can dissolve or 
disintegrate in oral cavity, have attracted a great deal of attention. 
Indeed, the FDT is an important and attractive alternative to liquid dosage form. 
Syrups are best for paediatrics but they are bulky and drugs are not as stable in liquid form 
as in solid form like tablets. 
FDT are characterized by high porosity and low hardness, when administered an 
in-situ suspension is created in the oral cavity as the tablet disintegrates and is 
subsequently swallowed. Some tablets are designed to dissolve in saliva remarkably fast, 
within a few seconds, and are true FDT. Others contain agents to enhance the rate of tablet 
disintegration in the oral cavity, and are more appropriately termed fast-disintegrating 
tablets, as they may take up to a minute to completely disintegrate. When put on tongue, 
this tablet disintegrates instantaneously, releasing the drug, which dissolves or disperses in 
the saliva. Some drugs are absorbed from the mouth, pharynx and oesophagus as the 
saliva passes down into the stomach. In such cases, bioavailability of drug is significantly 
greater than those observed from conventional tablet dosage form. The disintegration time 
of these tablets depend largely on size and hardness parameters. 
 
Fig. No. 1.1 Absorption of drug from intact tablet 
 1.2.2 Criteria for Fast Dissolving Drug Delivery System:
2
 
 The tablets should not require water to swallow, but it should dissolve or 
disintegrate in the mouth in matter of seconds. 
 Be compatible with taste masking. 
 Be portable without fragility concern. 
 Have a pleasant mouth feel. 
 Leave minimum or no residue in the mouth after oral administration. 
 Exhibit low sensitive to environmental condition as temperature and humidity. 
 Allow the manufacture of the tablet using conventional processing and packaging 
 Equipments at low cost. 
1.2.3 Requirements of FDT: 
An ideal FDT should 
 Require no water for oral administration, yet dissolving/disperse/disintegrate in a 
matter of seconds.  
 Leave minimal or on residue in mouth after administration. 
 Be harder and less friable. 
 Exhibit low sensitivity to environment condition (temperature and humidity). 
 Allow the manufacture of tablet by using conventional processing and packing 
equipment. 
1.2.4 Advantages of FDT: 
 Ease of administration to patient who refuses to swallow a tablet, such as 
paediatric, geriatric, and psychiatric patient.  
 No need of water to swallow the dosage form, which is highly convenient feature 
for patient who are travelling and do not have immediate access to water. 
 Convenience of administration and accurate dosing as compared to liquid. 
 Rapid dissolution of drug and absorption, which may produce rapid, onset of 
action. 
 Ability to provide advantage of liquid medication in the form of solid preparation. 
 Some drugs are absorbed from the mouth and oesophagus as the saliva passes 
down into the stomach in such cases bioavailability of drug is increased. 
 Pregastric absorption can result in improved bioavailability and as a result of 
reduced dosage, improved bioavailability and as a result of reduced dosage 
improved clinical performance through a reduction of unwanted effect. 
 Achieve increased bioavailability/rapid absorption through pregastric absorption 
of drug from mouth, pharynx and oesophagus as saliva passes down. 
 The risk of chocking or suffocation during oral administration of conventional 
formulation due to physical obstruction is avoided, thus providing improved 
safety. 
1.2.5 Disadvantages of FDT: 
 The tablets may leave unpleasant taste and/or grittiness in mouth if not formulated 
Properly 
 The tablets usually have insufficient mechanical strength. Hence, careful handling 
is required. 
 Tablets are very fragile and lack physical resistance. Because the tablets are very 
porous and low compression forces are used to prepare them. They cannot be 
packed in conventional strips or in bottles and special packaging is required.  
 Bitter drugs have to be taste masked by various techniques which in turn increases 
the time  and cost of production 
 
1.2.6 Silent feature of Fast Dissolving Drug Delivery System: 
 Ease of administration for patients who are mentally ill, disabled and 
uncooperative.  
 Quick disintegration and dissolution of the dosage form.                                                    
 Overcomes unacceptable taste of the drugs. 
 Allows high drug loading.                                                                                                             
 Ability to provide advantages of liquid medication in the form of solid preparation.            
1.2.7 Mechanism of tablet disintegrates 
5
: 
Capillary action 
 
Swelling 
   Because of heat of wetting 
Disintegrating particle/particle repulsive forces 
 
Deformation 
 
Release of gases 
 
Enzymatic action 
 
 
i) Capillary action: 
Disintegration by capillary action is always the first step. When we put the tablet 
into suitable aqueous medium, the medium penetrates into the tablet and replaces the air 
adsorbed on the particles, which weakens the intermolecular bond and breaks the tablet 
into fine particles. Water uptake by tablet depends upon hydrophilicity of the drug 
/excipients and on tableting conditions. For these types of disintegrates maintenance of 
porous structure and low interfacial tension towards aqueous fluid is necessary which 
helps in disintegration by creating a hydrophilic network around the drug particles. 
ii) Swelling:      
Perhaps the most widely accepted general mechanism of action for tablet 
disintegration is swelling Tablets with high porosity show poor disintegration due to lack 
of adequate swelling force. On the other hand, sufficient swelling force is exerted in the 
tablet with low porosity. It is worthwhile to note that if the packing fraction is very high, 
fluid is unable to penetrate in the tablet and disintegration is again slows down. 
                        
                    Fig. No. 1.2 Disintegration of tablet by wicking and swelling 
 
Fig. No. 1.3 Bulk swelling and water uptake apparatus 
The apparatus is useful for the quantification of swelling and hydration rates for 
many excipients and polymers. Swelling tests depends on number of variables including 
water transport and rate of hydration through membrane. This metho is used to evaluate 
intrinsic swelling through the use of high speed cinemicroscopy in conjuction with 
computerized image analysis. 
iii) Heat of wetting (air expansion): 
When disintegrates with exothermic properties gets wetted, localized stress is 
generated due to capillary air expansion, which helps in disintegration of tablet. This 
explanation, however, is limited to only a few types of disintegrates and cannot describe 
the action of most modern disintegrating agents. 
iv) Disintegrating particle / particle repulsive forces: 
Another mechanism of disintegration attempts to explain the swelling of tablet 
made with ‗non-swellable‘ disintegrates.  Guyot-Hermann has proposed a particle 
repulsion theory based on the observation that non-swelling particle also cause 
disintegration of tablet. The electric repulsive forces between particles are the mechanism 
of disintegration and water is required for it. Researchers found that repulsion is 
secondary to wicking. 
v) Deformation:  
Hess had proved that during tablet compression, disintegrated particles get 
deformed and these deformed particles get into their normal structure when they come in 
contact with aqueous media or water. Occasionally, the swelling capacity of starch was 
improved when granules were extensively deformed during compression. This increase in 
size of the deformed particles produces a breakup of the tablet. 
                           
                         Fig. No. 1.4 Disintegration by deformation and repulsion
 
vi) Release of gases: 
Carbon dioxide released within tablets on wetting due to interaction between 
bicarbonate and carbonate with citric acid or tartaric acid. The tablet disintegrates due to 
generation of pressure within the tablet. This effervescent mixture is used when 
pharmacist needs to formulate very rapidly dissolving tablets or fast disintegrating tablet. 
As these disintegrates  are highly sensitive to small changes  in humidity level and 
temperature ,strict control of environment is required during manufacturing of the tablets 
.The effervescent blend is either added immediately prior to compression or can be added 
in to two separate fraction of formulation. 
vii) Enzymatic reaction: 
Here, enzymes presents in the body act as disintegrates. These enzymes destroy 
the binding action of binder and helps in disintegration. 
viii) Fundamentals of fast dissolving /disintegrating tablets: 
For rapid dissolution or disintegration of dosage form, water must rapidly 
penetrate into the tablet matrix to cause quick disintegration & instantaneous dissolution 
of the tablet. Several techniques are used to achieve these fundamentals, to formulate 
mouth-dissolving tablet. Some of the techniques are described below. 
 
1.3 FORMULATION PROCESSES FOR MAKING FDT 
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: 
There are several technologies that produce commercially available FDTs. Zydis 
(Cardinal Health, Dublin, Ohio), OraSolv/DuraSolv (Cima Labs, Eden Prairie, 
Minnesota), and WOWTAB (Yamanouchi Pharma Technologies, Norman, Oklahoma) are 
widely known technologies (Table 1). Some of the FDT products on the market are listed 
in Table 2. Although these technologies meet the special requirements for FDTs to some 
extent, none has all the desired properties. The currently available technologies have been 
reviewed in the literature. The technologies are usually grouped according to the method 
used in making FDTs, such as freeze drying, molding and compression; compression is 
the most widely used method for making FDTs. Some methods are focused on unique 
granulation methods, such as spray-drying and flash-heating, to make shear form 
formulations; some are focused on selecting specific excipients such as water-insoluble 
calcium salt, specific disintegrants combination, and specific sugar combination; and 
some are focused on special treatment after compression, such as sublimation, sintering, 
and humidity treatments. Each method is examined in more detail below. 
1.3.1 Freeze Drying: 
Freeze drying (lyophilization) is a process in which solvent is removed from a 
frozen drug solution or a suspension containing structure-forming excipients. The 
resulting tablets are usually very light and have highly porous structures that allow rapid 
dissolution or disintegration. When placed on the tongue, the freeze dried unit dissolves 
almost instantly to release the incorporated drug. The entire freeze drying process is done 
at non elevated temperatures to eliminate adverse thermal effects that may affect drug 
stability during processing. When stored in a dried state, the freeze-dried dosage form has 
relatively few stability problems during its shelf life. The freeze-drying process may result 
in a glassy amorphous structure of excipients as well as the drug substance, leading to the 
enhanced dissolution rate. Freeze drying, however, is a relatively expensive 
manufacturing process, and the formulation has poor stability at higher temperature and 
humidity. 
The Zydis technology is the most well known example of the freeze drying 
method. In the Zydis formulations, the drug is physically trapped in a matrix composed of 
two components, a saccharide (e.g., mannitol) and a polymer. The carrier polymers 
commonly used in the Zydis system include (par tially hydrolyzed) gelatin, hydrolyzed 
dextran, dextrin, alginates, poly (vinyl alcohol), polyvinylpyrrolidone, acacia, and the 
mixtures.  After the solution or dispersion is filled into blister cavities, it is then frozen in 
a liquid nitrogen freezing tunnel. The solvent in the frozen state is removed to produce 
porous wafers. Because the units are fragile and light-weight, they cannot withstand the 
pressure of being pushed through the foil of a conventional blister. A special peelable 
backing foil is used to package the Zydis units. Because the water content in the final 
freeze-dried product is too low for microbes to grow, the Zydis formulation is also self-
preserving.  
However, the Zydis formulation is so sensitive to moisture that the tablet may melt 
between sweaty fingers when it is taken out of the package. This dosage form may 
degrade at humidity greater than 65%, so a pinhole or minor damage to the package will 
lead to collapse of the tablet. There are some requirements for the Zydis technology. The 
drug should be chemically stable and water insoluble, with a particle size smaller than 50 
μm. Precipitation may occur during manufacturing if large drug particles are used. The 
water soluble drugs may form eutectic mixtures that cannot be frozen adequately to form 
the rigid structure necessary to support itself after solvent is removed, which may cause 
collapse of the freeze dried cake. For this reason, the dose for water-soluble drugs is 
usually limited to 60 mg. Higher drug dosing can be accommodated without losing the 
rapid disintegration property, however, if a thickened (i.e., paste-like) form of an oil-in-
water emulsion is directly placed in the blister cell. There are 13 products currently 
available based on the Zydis technology.  
 
Fig. No. 1.5 Zydis dosage form and blister pack 
The products on the US market include Claritin Reditab, Dimetapp Quick 
Dissolve, Feldene Melt, Maxalt-MLT, Pepcid RPD, Zofran ODTR, and Zyprexa ZydisR. 
In the worldwide market, oxazepam, lorazepam, loperamide, and enalapril are available in 
the Zydis formulations (Table 1).   
Quicksolv (Janssen Pharmaceutica, Beese, Belgium) and Lyoc (Farmalyoc 
Laboratorie L., Lefon, Maisons-Alfort, France) are also prepared by the freeze drying 
method. In the Quicksolv formulation, the matrix compositions are dissolved in the first 
solvent (usually water), and then the solution is frozen. At the temperature at which the 
first solvent will remain in the solid form, the frozen solution contacts the second solvent, 
which is substantially miscible with the first solvent. For example, ethanol, menthol, or 
acetone is used as the second solvent with water as the first solvent. The matrix 
composition should be immiscible to the second solvent. Thus, the first solvent is 
substantially removed after a few hours of contacting the second solvent to result in a 
usable matrix. The final product disintegrates almost instantly. This method is claimed to 
prevent or reduce the incidence of cracking during the final preparation, having uniform 
porosity and adequate strength for handling. In the Lyoc formulation, the porous solid 
form is obtained by freeze drying an oil-in-water emulsion placed directly in the blister 
pockets. In order to prevent in-homogeneity by sedimentation during freeze drying, this 
formulation requires a large proportion of undissolved inert filler to increase the viscosity 
of the suspension. The high proportion of filler reduces the porosity of the tablet, and as a 
result, the disintegration is slower. It is also noted that the tablet still has poor mechanical 
resistance. 
NanoCrystal technology (Elan, King of Prussia, Pennsylvania) uses orally 
administered nanoparticles (<2 μm) in the form of rapidly disintegrating tablet matrix. 
The NanoCrystal orally disintegrating tablet dosage form was developed to facilitate the 
preparation of small-scale clinical supplies. NanoCrystal colloidal dispersions of drug 
substance are combined with water-soluble ingredients, filled into blisters, and 
lyophilized. This approach is especially attractive when working with highly potent or 
hazardous materials because it avoids manufacturing operations such as granulation, 
blending, and tableting, which generate large quantities of aerosolized powder and present 
much higher risk of exposure. The freeze-drying approach also enables small quantities of 
drug to be converted into FDTs because manufacturing losses are negligible. The final 
tablet is durable enough for conventional blister or bottle packaging and accepts as much 
as 200 mg of drug per unit. Other features include conventional, compendial inactive 
components and non-moisture sensitive inactive ingredients. 
 
1.3.2 Molding: 
The major components of molded tablets typically are water-soluble ingredients. 
The powder mixture is moistened with a solvent (usually ethanol or water), and then the 
mixture is molded into tablets under pressures lower than those used in conventional 
tablet compression. (This process is known as compression molding.) Then the solvent 
can be removed by air-drying. Because molded tablets are usually compressed at a lower 
pressure than are conventional compressed tablets, a higher porous structure is created to 
enhance the dissolution. To improve the dissolution rate, the powder blend usually has to 
be passed through a very fine screen. Recently, the molded forms have also been pre 
pared directly from a molten matrix in which the drug is dissolved or dispersed (known as 
heat molding) or by evaporating the solvent from a drug solution or suspension at ambient 
pressure (novacuum lyophilization). Solid dispersion also can be used to make the tablets. 
The drug can remain discrete particles or microparticles dispersed in the matrix. It can 
dissolve totally in the molten carrier to produce a solid solution or dissolve partially in the 
molten carrier while the remaining undissolved particles disperse in the matrix. The 
characteristics of the tablets (such as disintegration time, drug dissolution rate, and mouth 
feel) vary based on the type of the dispersion or dissolution. Because of their water-
soluble sugar components, molded tablets disintegrate more rapidly and offer improved 
taste. However, molded tablets typically do not have great mechanical strength.  The 
chance of erosion and breakage of the molded tablets during tablet handling and opening 
blister pockets is high. If hardness enhancing agents are added to the formulation, the rate 
of tablet disintegration usually decreases. Mechanical strength and good disintegration of 
the tablets can be improved by using nonconventional equipment and/or multistep 
processes. Using a nonconventional approach, however, requires substantially larger 
investment in machinery. Compared with freeze-drying, molded tablets can be produced 
more simply and efficiently at an industrial scale, although disintegration times may not 
be com parable to those of lyophilized forms. Takeda Chemical Industries (Osaka, Japan) 
and Nippon Shinyaku (Kyoto, Japan) have disclosed in compression-molding. The wetted 
mass was compressed at low pressure and subsequently dried to produce porous tablets 
with sufficient mechanical strength. The disintegration time was about 30–50 seconds in 
the mouth. In a patent by Novartis Consumer Health (Basel, Switzerland), the drug 
solution or suspension was dispersed into molds. The solvent was removed from the units 
usually by heating, pressure reduction, or microwave radiation. In a patent by Okada, the 
molded tablets contained a drug, a saccharide having a solubility of 30 (w/w) % or less at 
room temperature (e.g., lactose and mannitol), and a saccharide having a solubility of 30 
(w/w) % or more at room temperature (e.g., glucose, fructose, sucrose, xylose, trehalose, 
xylitol, sorbitol, erythritol, dextrin, and pullulan). The amount of this saccharide was 
slightly above its solubility. The mixture was a creamy aqueous suspension having both 
low solubility and high solubility saccharides in water. The moisture was then removed 
from the suspension to obtain molded tablets. 
1.3.3 Compaction: 
Using a conventional tablet press to make fast-dissolving tablets is a very 
attractive method because of the low manufacturing cost and ease in technology transfer. 
However, the tablet press has been designed to make conventional tablets. When making 
conventional tablets, maintaining high tablet porosity is not a primary concern, and high 
compression force is used to ensure the tablet strength. Many strategies have been tried to 
achieve high porosity and adequate tablet strength using a tablet press. First several 
granulation methods have been tried to obtain granules suitable for making FDTs. Wet 
granulation, dry granulation, spray drying, and flash heating methods have been tried. The 
second approach is to select special types of excipients as the main component for FDTs. 
The third approach is to compress tablets at low pressure and apply various after-
treatments to the soft tablets. The three most widely used approaches are described in 
detail below. 
i) Granulation methods: 
a. Wet granulation: 
It was found that even with effervescent agents presented in the tablet with lower 
than 5%, quick disintegration times could be achieved. Furthermore, it was also found that 
fast disintegration time could be achieved using only the acid component of the 
effervescent couple. In the patent, the formulation includes polyalcohols (e.g., mannitol, 
xylitol, sorbitol, maltitol, erythritol, and lactitol), 1–30% of an edible acid, and an active 
ingredient as the dry mixture. This mixture was wet granulated with an aqueous solution 
of a water-soluble or water-dispersible polymer (e.g., poly(ethylene glycols), carrageenan, 
and ethylcellulose), which consisted of 1–10% of the final weight of the granule in a fluid 
bed. Granules with high porosity and low apparent density were obtained, and the tablets 
made by such granules had rapid disintegration times ranging from 3 to 30 seconds in the 
saliva.  
b. Dry granulation: 
Higher density alkali earth metal salts and water-soluble carbohydrates usually do 
not provide quick disintegration and a smooth mouth feel. Low-density alkali earth metal 
salts and water soluble carbohydrates are also difficult to compress and caused inadequate 
content uniformity. For these reasons, low-density alkali earth metal salts or water-soluble 
carbohydrates were precompacted, and the resulting granules were compressed into 
tablets that could dissolve fast. In this process, a powdered material with a density of 0.2–
0.55 g/mL was precompacted to increase the density to 0.4–0.75 g/ml by applying a force 
ranging from 1 to 9 kN/cm. The resulting granules were compressed into tablets. 
c. Melt granulation: 
A new approach of preparing FDTs with sufficient mechanical strength, involving 
the use of a hydrophilic waxy binder (SuperpolystateR, PEG-6-stearate) by melt 
granulation or wet granulation. Because SuperpolystateR is a waxy material with a 
melting point of 33–37 °C and a hydrophilic to lipid balance (HLB) value of 9, it will not 
only act as a binder and increase the physical strength of tablets but also help the 
disintegration of the tablets. In case of melt granulation, granules were prepared in a high-
speed blade mixer at 40–44 °C, according to the conventional hot-melt procedure. For wet 
granulation, an oil-in-water emulsion of SuperpolystateR was used as the granulating 
agent. Then, granules were blended with crosscarmellose, aspartame, and magnesium 
stearate and compressed into tablets. The melt granulation FDTs had better hardness 
results than the wet granulation FDTs. The disintegration times of melt granulation 
tablets, however, was more than 1 minute. 
d. Spray drying: 
Spray drying methods are widely used in pharmaceutical and biochemical 
processes. Spray drying provides a fast and economical way of removing solvents and 
producing highly porous, fine powders. Allen and Wang produced a particulate support 
matrix for use in making FDTs by a spray-drying technique. The components included 
supporting agents composed of two polypeptide components of the same net charge 
(preferably nonhydrolyzed and hydrolyzed gelatin), a bulking agent (mannitol), and a 
volatilizing agent. To maintain the net charges of the polypeptide components, an 
acidifying or alkalinizing agent was included. The mixtures of the above components 
were spray dried to obtain porous granules. The reason to use polypeptide components of 
the same charge was that molecules would repel each other even after spray drying, so 
porous and low-bulk-density particles could be formed. By incorporating a volatilizing 
agent (ethanol in most cases), the surfacetension of the droplets was further reduced 
during spray drying, and more pores and channels were created. The dissolution rate of 
the matrix was further increased when combined with a bulking agent. A minimal amount 
of an effervescent agent was optionally included to further accelerate the dissolution rate. 
To aid in keeping the tablets intact during handling, a thin coating of polymeric material 
could be applied externally. This coating should not inhibit the capillary uptake of water 
during dissolution. Active ingredients can be microencapsulated or nanoencapsulated to 
further achieve taste masking. 
e. Flash heat process: 
Fuisz Technologies (Chantilly, Virginia) has introduced the Shearform 
Technology to make Flashdose. The Shearform Technology uses a unique spinning 
mechanism to produce a floss-like crystalline structure, much like cotton candy. In this 
process, the feedstock is subjected to centrifugal force and to a temperature gradient 
simultaneously. An internal flow is created by this condition to force the fl owing mass 
out of the opening provided in the perimeter of a spinning head. The mass is cooled down 
as it comes out of the opening to form a discrete fiber structure, as seen in cotton candy. 
The speed of spinning is about 3,000–4000 rpm, and the temperature gradient is about 
180–250°C. The carrier materials include saccharides, polysaccharides, and mixtures 
thereof. There were two systems used to create the Shearform floss having self-binding 
properties. The first system was named a single floss or unifloss. Typical flosses of this 
kind, made of sucrose, sorbitol, and xylitol, yielded effective selfbinding properties. The 
second system used two separate flosses. One was xylitolcontaining binder flosses and the 
other was base flosses that contain different sugar alcohols or saccharide. When the two 
flosses were combined, it was termed a dual floss system. The produced floss needed to 
be recrystallized to form freely flowing granules with self-binding properties. Two 
techniques were used in recrystallization. One was using crystallization enhancers 
including ethanol, polyvinylpyrrolidone, water (e.g., moisture), glycerin, and radiant 
energy (e.g., microwaves). The other was using crystallization modifiers, which were 
included in floss ingredients at 0.01–20.0% the weight of the floss. Typical crystallization 
modifiers were surfactants having an HLB of about 6 or more. A hygroscopic material 
such as xylitol must be present in the system to provide good self-binding characteristics 
to the final matrices. In order to produce and control the self-binding properties, this 
hygroscopic material must have a substantially higher hygroscopicity than that of the 
carrier carbohydrate (e.g., sucrose). The initial floss coming out of the spinning machine 
is in its amorphous state. However, because of its tendency to pick up moisture in the floss 
and induce crystallization by crystallization enhancers or modifiers, the floss recrystallizes 
into a more crystalline structure. Because of intimate contacts among all components in 
the matrix, recrystallization of one component can have significant impact on the 
characteristics of surrounding components and further change the properties of the matrix 
as a whole. The floss gradually loses its amorphous character as the recrystallization 
continues. The flowability of the floss is enhanced to make it suitable for the conventional 
tableting process.  
 
ii) Direct compression: 
From the pharmaceutical manufacturer‘s point of view, direct compression is the 
simplest and most cost-effective tablet manufacturing procedure. Pharmaceutical 
companies can use conventional manufacturing equipment and commonly available 
ingredients. This method can be applied to manufacturing FDTs by choosing appropriate 
combinations of excipients, which can provide fast disintegration and good physical 
resistance. Sugar-based excipients have been widely used as bulking agents because of 
their high aqueous solubility and sweetness, pleasing mouth-feel and good taste masking. 
Nearly all formulations for FDTs incorporate some sugar materials in their formulations.  
a. Disintegrants used in FDT:  
Some patents use effervescent couples as their disintegrant, while others use a 
combination of disintegrants.  
Dobetti summarized different types of non-effervescent disintegrants used in the 
pharmaceutical area.  
• Starch and modified starches. This group includes natural starches (such as maize 
starch and potato starch), directly compressible starches (such as starch 1500), modified 
starches (such as carboxymethylstarches and sodium starch glycolate), and starch 
derivatives (such as amylose). 
• Cross-linked polyvinylpyrrolidone 
• Modifi ed celluloses such as cross-linked sodium carboxymethylcellulose 
• Alginic acid and sodium alginate 
• Microcrystalline cellulose 
• Methacrylic acid-divinylbenzene copolymer salts 
In addition, poly (acrylic acid) superporous hydrogel (SPH) microparticles were 
recently reported as superdisintegrants possessing a unique porous structure.31 They were 
used as a wicking agent to decrease the disintegration time of FDTs. The poly(acrylic 
acid) SPH microparticles can swell approximately 80 times in distilled water and 50 times 
in pH 6.8 which contains 0.2 M phosphate buffer. The SPH microparticle size had a 
significant effect on the disintegration time and tensile strength of ketoprofen FDTs. The 
minimum disintegration time was observed when the microparticle size was in the range 
of 75-106 μm. Tensile strength of the tablets decreased as the SPH microparticle sizes 
decreased from 180-250 μm to 25-44 μm. However, when the microparticle sizes were 
smaller than 25 μm, the tensile strength of the resultant tablets increased as the size 
decreased. The optimal microparticle size should be in the range of 75-106 μm. The FDTs 
made of SPH microparticles in the range of 75-106 μm showed the fastest disintegration 
time (15.0 ± 2.0 s) and higher tensile strength (84.4 ± 4.1 N/cm2). 
b. Inorganic excipients used in FDT: 
Dobetti has developed a formulation using insoluble inorganic excipients as the 
main component for FDTs. According to the patent, disintegration of a tablet depends on 
the quantity of the disintegrant and insoluble inorganic excipient used. The disintegration 
also depends on the relative weight ratio between the water insoluble and soluble 
excipients, if the water-soluble excipients are used. It was also found that in their 
formulations, sufficient compression could be applied to form tablets with strong tensile 
strength and low friability. The disintegration rates were not significantly affected by the 
high compression force. In the formulation, three major components were used:  
• Substantially water insoluble components: This group includes water-insoluble 
excipients, water-insoluble drugs (either coated or uncoated), and water- insoluble 
lubricant and glidant. The water-insoluble excipients include insoluble inorganic salt (e.g., 
di- or tri-basic calcium phosphate) or organic filler (e.g., microcrystalline cellulose). 
• Substantially soluble components: This group includes compressible sugars, 
flavouring agents, sweeteners, binders, and surfactants. 
• Disintegrants: Examples are maize starch or modified starch, cross-linked 
polyvinylpyrrolidone, or sodium carboxymethylcellulose.  
The disintegration time increased as the amount of insoluble component 
decreased. If the active ingredient was only a small portion of the whole formulation, the 
disintegration time could be optimized by including insoluble fillers (e.g., microcrystalline 
cellulose and silicon dioxide) or by increasing the amount of insoluble inorganic 
excipients (e.g., calcium salt such as dibasic calcium phosphate).  
iii) Compaction and subsequent treatments: 
a. Sublimation: 
The slow dissolution of the compressed tablet containing even highly water-
soluble ingredients is due to the fact that the low porosity of the tablets reduces water 
penetration into the matrix. When volatile materials are compressed into tablets using the 
conventional method, they can be removed via sublimation, resulting in highly porous 
structures. The volatile materials include urea, ammonium carbonate, ammonium 
bicarbonate, hexa methylene tetramine, and camphor. Heinemann disclosed a process to 
prepare porous tablets by sublimation. The mixtures of volatile adjuvants were made into 
tablets, which were subsequently heated to remove them. Roser and Blair used vacuum to 
remove the volatile materials. The full dissolution time was reduced from 10–15 minutes 
for the tablets formed from trehalose alone to less than 1 minute. In some cases, menthol, 
camphor, thymol, an organic acid such as adipic acid, and a lower fatty acid such as 
arachidic acid, capric acid, myristic acid, and palmitic acid were used as the volatile 
materials, and the sublimation temperature ranged from 40 to 60 °C. The disintegration 
time in the human mouth was claimed to be about 25 seconds.  
Lo disclosed an efficient method for preparing high-strength, highly porous, fast-
dissolving delivery devices. In this method menthol, a water-soluble, mentholsoluble 
polymer, and an active ingredient are mixed at a temperature that insures that the menthol 
is substantially molten. The formulation is disposed in a mold and solidified, and the 
menthol is sublimed from the solidified molded formulation. Preferably, the solidification 
occurs at a temperature sufficient to provide a substantially amorphous menthol structure. 
b. Humidity Treatment: 
The mechanical strength of some tablets increased substantially after moisture 
treatment, compared with the tablets before the treatment. The increase is known to be due 
to the formation of liquid bridges in the presence of moisture and then formation of solid 
bridges after drying. As shown in Fıg. No.1.6, when solid particles start to pick up 
moisture from the atmosphere, the water is adsorbed onto the surface (A), and then water 
molecules form a film on it with the vapor pressure over the adsorbed moisture layer 
equal to Pb (B). The solid starts to dissolve into the adsorbed moisture layer and the 
dissolution of solid in the adsorbed moisture will lead to a decrease in the vapor pressure 
Pb (C). The decrease in Pb is effectively off set by the increase in temperature of the film 
(and the solid) caused by the heat released on condensation of the water vapor. The 
moisture sorption occurs spontaneously, and the thickness of the condensate film grows as 
long as Pa > Pb. The solid continues to dissolve and saturate the fi lm, maintaining the 
vapor pressure over the adsorbed moisture layer (Pb). After drying, a solid bridge is 
believed to occur and increase bonding between the particles (D). It is also known that 
certain types of sugar change from the amorphous to the crystalline state when their 
solution is spray dried or used as a binder solution. Further investigations have shown that 
when an amorphous sugar is treated to go through the humidification and drying process, 
it changes to a crystalline state. This change increases the tablet strength substantially. 
The conceptual process of structural changes of amorphous sucrose to crystalline sucrose 
is shown in Fıg. No.1.7. 
 
Fig.No.1.6 moisture sorption model explaining the increase mechanical strength of 
FDT 
 
 Fig.No.1.7 model describing the increase in tablet strength by transformation of 
amorphous sucrose to crystalline sucrose upon storing under a certain relative 
humidity 
In a patent by Mizumoto et al., a drug, a sugar, and an amorphous sugar capable of 
transforming from amorphous to crystalline state were mixed and compressed into tablets. 
After the tablets were formed, they were humidified and dried. The amount of the sugar in 
the formulation can be adjusted according to the drug content and tablet size. The 
―amorphous sugars‖ are those that can form an amorphous state by spray drying, freeze 
drying, or other granulation methods. These amorphous sugars include glucose, lactose, 
maltose, sorbitol, trehalose, lactitol, and fructose. The relative humidity is determined by 
the apparent critical relative humidity of the mixture of a drug and an amorphous sugar. A 
relative humidity greater than or equal to the critical relative humidity of this mixture is 
chosen for the humidity condition. The advantage of using amorphous sugars is that they 
have low critical relative humidity, so that they can absorb water even at low moisture 
levels. The crystalline form of the sugars has difficulty in controlling moisture absorption. 
Moisture absorption of the crystalline form is not sufficient to strengthen the tablets at a 
low humidity condition. If a high humidity condition is used, tablets may adhere together, 
causing manufacturing problems. Another advantage of using amorphous sugars is that 
transformation of the amorphous state to the crystalline state is irreversible. The sugars in 
crystalline state have a high critical moisture point, so the strengthened tablets are less 
susceptible to moisture. System for making FDTs by humidity treatment consist following 
steps: (1) a water-soluble polymer was used as a binder solution to granulate active 
ingredients and other excipients, such as low modability sugars; (2) the granules were then 
compressed into tablets; (3) the tablets were humidified at relative humidity of about 50–
100%; and (4) the tablets were dried. The hardness of the tablet was about 0.5–12.0 
kilopounds, and the in vivo disintegration time was claimed to be about 1–40 seconds. 
 Fig.No.1.8 Schematic view of the manufacturing apparatus using moisture treatment  
The left side of a dotted line shows the conventional compression and dedusting 
steps, while the right side shows the additional step requiring special chambers for 
moisture treatment and drying. 
Tatara et al. also used moisture treatment and devised an apparatus to handle the 
fragile tablets before moisture treatment. An active ingredient and other excipients were 
compressed in low pressure, and then the resultant tablets were moisturized and dried to 
produce porosity between 20 and 40%. the manufacturing apparatus includes a rotary 
punch-press, a relay conveyor for transferring tablets, a moisturizing section, a drying 
section, and a delivery conveyor. In the moisturizing section, the condition was set to 
allow tablets moisturized at 45 °C, 95% relative humidity for 60 seconds. In the drying 
section, the temperature was set to 50 °C for 60 seconds. With this apparatus the fragile 
tablets before moisture treatment were gently transferred throughout the process.  
c. Sintering: 
Lagoviyer et al. disclosed a process that increased tablet strength by sintering the 
tablet components at high temperatures and then resolidifying them at lower temperatures. 
The components in this formulation include bulk agents, structure agents, solvent, and 
binding agents. A bulk agent in this formulation is used to provide bulk volume to the 
overall tablet, and suitable agents include carbohydrates, calcium carbonate, and 
magnesium carbonate. The suitable structure agents should provide dedusting, 
moisturizing, drying and conventional compression steps. The left side of a dotted line 
shows the conventional compression and dedusting steps, while the right side shows the 
additional step requiring special chambers for moisture treatment and drying. A porous 
support structure to allow quick dissolution of the tablets in the mouth. The structural 
agents include agar, gelatin, albumin, and chondroitin. Bulking and structural agents were 
dissolved in a suitable solvent, and the dissolved mixture was spray dried or dispersed to 
obtain a bead or granulated product with a low density. Choice of the solvent is based on 
its ability to provide a desired porosity to the bead or granulated product upon drying. 
Solvents can be chosen from water, ethyl alcohol, isopropyl alcohol, or a mixture thereof. 
The binders need to melt at the sintering stage, form bonding among granules, and 
resolidify as the temperature of the final sintering or heating step decreases. Binders are 
water soluble polymers such as poly (ethylene glycol) (PEG), with a molecular weight of 
approximately 1000 to 1,000,000. PEG melts at 50–90 °C. PEG has the advantage of 
functioning both as a binder and as a capillary attractant. The amount of binding polymer 
ranged from 0.5% to 25% of the weight of the final product. The binding agents and 
active ingredients can be introduced to the formulation in several ways. A binding agent 
and active ingredient can also be dry blended to the spray-dried or dispersed granulated 
product. They can alternatively be dissolved into solvent with bulking agent and spray 
dried into granules. The granules are then lightly compressed to form tablets. These 
tablets are heated for a sufficient time and temperature to allow the binding agent to melt. 
The heating step is intended to melt the binding agent to create intra-tablet bonds and help 
weld the product shape together. Typically, a laboratory oven is set at around 50–100 °C. 
The heating time ranges from 3 to 45 minutes. The binding agents are resolidified as the 
temperature is reduced to ambient temperature. The disintegration time is generally within 
3–60 seconds. The heat treatment or sintering step in the patent improved the product‘s 
strength and durability. Because the active ingredient can be introduced into the 
formulation in several ways, taste-masking technologies can be easily incorporated into 
the process. The dosage form allows the incorporation of a wide range of dosage levels. 
Because of the high temperature treatment, when heat-labile drugs are incorporated in the 
formulation, careful attention should be given in this process. These technologies are 
commonly applied for the production and development of FDTs. 
1.4 FDT FORMULATION TECHNOLOGY: 
Because the direct compression is most desirable in terms of producing FDTs with 
high mechanical strength, ease of manufacturing, and low cost, currently available FDT 
formulations using direct compression are described in detail. 
1.4.1. OraSolv and DuraSolv Technology 
7
: 
OraSolv technology (Cima Labs) produces tablets by low compression pressure. It 
uses an effervescent disintegration pair that releases gas upon contact with water. The 
widely used effervescent disintegration pairs usually include an acid source and a 
carbonate source. The acid sources include citric acid, tartaric acid, malic acid, fumaric 
acid, adipic acid, and succinic acids. The carbonate sources include sodium bicarbonate, 
sodium carbonate, potassium bicarbonate, and potassium carbonate. The carbon dioxide 
evolved from the reaction may provide some ―fizzing‖ sensation, which is a positive 
organoleptic sensation. The amount of effervescent agent is in general about 20–25% of 
the total weight of the tablet. Because of the soft and fragile nature of OraSolv tablets, a 
special packaging system, known as PakSolv, was developed to protect the tablets from 
breaking during transport and storage. PakSolv is a ―dome-shaped‖ blister package that 
prevents the vertical movement of the tablet within the depressions, because the diameter 
of the lower portion of the dome is too narrow to accommodate the tablet. PakSolv also 
offers light, moisture, and child resistance. As a second-generation technology, the 
DuraSolv technology was developed by Ciba to provide stronger tablets for packaging in 
blisters or bottles. The key ingredients in this formulation are nondirect compression filler 
and lubricant. The particle size of the nondirect compression filler is preferably between 
about 20 and 65 μm, while for direct compressible fillers at least 85% of the particles are 
over 100 μm in size. These nondirect compression fillers, such as dextrose, mannitol, 
sorbitol, lactose, and sucrose, have the advantage of quick dissolution and avoid some of 
the gritty or sandy texture usually present in direct compressible versions of the sugar. 
The amount of a nondirect compression filler is usually about 60–95% of the total tablet 
weight. The tablets have low friability, which is about 2% or less when tested according to 
the USP, and the hardness of the tablets is at least about 15–20 N. The disintegration time 
is less than 60 seconds. About 1–2.5% of lubricant can be added to the formulation, 
compared with 0.2–1% of lubricant in conventional tablets. The lubricant blending times 
can also be increased to 10–25 minutes or longer. Relatively modest compressive force is 
needed to compress the formulation. This method can produce tablets by the direct 
compression method and use conventional tableting methodologies and conventional 
package equipment. Thus, the production cost is significantly decreased. 
 
 Fig. No. 1.9 Typical PakSolv package 
1.4.2. Wowtab Technology: 
WOWTAB technology employs a combination of low- and high-moldability 
saccharides to produce fast-dissolving tablets using conventional granulation and tableting 
techniques. According to the patent, saccharides were divided into two groups: those with 
high moldability and those with low moldability. Lowmoldability saccharides produce 
tablets with hardness between 0 and 2 kg, when 150 mg of such a saccharide is 
compressed under pressure of 10–50 kg/cm2 using a die 8 mm in diameter. The typical 
low-moldability saccharides include lactose, mannitol, glucose, sucrose, and xylitol. High-
moldability saccharides produce tablets with hardness above 2 kg when prepared under 
the identical conditions. The typical high- moldability saccharides are maltose, maltitol, 
sorbitol, and oligosaccharides. When tablets are made by compressing a saccharide having 
low moldability or high moldability alone, the desired properties of adequate hardness and 
quick disintegration in the mouth cannot be achieved simultaneously.  
Moreover, if saccharides having low moldability and high moldability are mixed 
(physical mixture) before tableting, quick disintegration and dissolution in the mouth 
cannot be obtained. As clearly indicated in the patents, there is no single saccharide that 
can make tablets having both high strength and fast disintegration properties. For this 
reason, a saccharide having low moldability was granulated with a saccharide having high 
moldability as a binder. The low-moldability saccharides were used as the main 
component. The tablets show an adequate hardness and fast disintegration and dissolution 
when put in the mouth. 
1.4.3. Flashtab Technology: 
Flashtab technology (Ethypharm, France) produces tablets by compression of 
granular excipients. This technology uses almost the same excipients as do conventional 
compressed tablets. Excipients used in this technology comprise two groups of 
components: disintegrating agents, such as carboxymethylcellulose or insoluble 
reticulated polyvinylpyrrolidone; and swelling agents, such as carboxymethylcellulose, 
starch, modified starch, carboxymethylated starch, microcrystalline cellulose, and possibly 
directly compressible sugars. The mixture of excipients is prepared by either dry or wet 
granulation methods. The produced tablets are known to have satisfactory physical 
resistance and disintegrate in the mouth within 1 minute. 
1.4.4. AdvaTab Technology: 
AdvaTab technology (Eurand) produces FDT tablets based on a proprietary tablet 
composition that was designed and patented by Kyowa Hakko Kogyo (Tokyo, Japan), in 
which the lubrication is dispensed onto each tablet by using a spray during the production 
process. Traditional tablets are produced using an internal lubrication system, which 
disperses lubricant on the inside and the surface of the tablets. This method can decrease 
tablet mechanical strength. AdvaTab is produce d using 10–30 times less hydrophobic 
lubricant and can be 30–40% stronger than conventional tablets. As a result, the tablets are 
hard and durable yet do not impede liquid entry upon contact with saliva. AdvaTab can 
handle high drug loading and coated drug particles. Importantly, the technology does not 
require specialty packaging and, as a result, can be packaged in both standard bottles and 
push-through blisters.  
1.4.5. Dispersible Tablet Technology: 
Lek in Yugoslavia was issued patents for dispersible tablets of dihydroergotoxine 
and cimetidine, which were claimed to disintegrate in less than 1 minute when in contact 
with water at room temperature. Dihydroergotoxine is poorly soluble in water in the free 
base form. An improved dissolution rate of dihydroergotoxine methanesulphonate was 
observed with dispersible tablets containing 0.8–10%, preferably about 4% by weight, of 
an organic acids. One of the essential excipients in the cimetidine formulation was a 
disintegrating agent. It provides rapid swelling and/or good wetting capability to the 
tablets and thereby a quick disintegration. The disintegrating agents include starch or 
modified starches, microcrystalline cellulose, alginic acid, cross-linked sodium 
carboxymethyl cellulose, and cyclodextrin polymers. A combination of two or more 
disintegrating agents produced better disintegration results. 
1.4.6. Pharmaburst Technology: 
Pharmaburst technology (SPI Pharma, New Castle, Delaware) uses off -the-shelf 
coprocessed excipients to create an FDT that, depending on the type of active and loading 
(up to 700 mg), dissolves within 30–40 seconds. The quantity of Pharmaburst required in 
a formulation depends on the active in the tablet. It is necessary to carry out initial studies 
on a formulation by varying the amount of Pharmaburst from 50 to 80%, depending on the 
desired mouth feel and disintegration time. The process involves a dry blend of a drug, 
flavor, and lubricant that are compressed into tablets on a standard tablet press with stock 
tooling. The manufacture process can be carried out under normal temperature and 
humanity conditions. The tablets can be packaged in blister packs or bottle. 
1.4.7. Frosta Technology: 
The core concept of Frosta technology is compressing highly plastic granules at 
low pressure to produce strong tablets with high porosity. The highly plastic granules 
comprise three classes of components: a porous and plastic material, a water penetration 
enhancer, and a binder. The highly plastic granules can then be compressed at low 
pressure to form a fast-melting pharmaceutical tablet. A porous, plastic material is water 
soluble or water dispersible, sometimes almost instantaneously upon contact with water. 
Plastic deformation of powders dramatically increases the chance of the interparticle 
contacts necessary to form bonds between particles. If a porous and plastic material is 
polymeric, it is essential to prevent formation of a viscous layer of the material at the 
tablet surface when it dissolves in aqueous medium. One way of making such tablets is to 
mix porous, plastic material with a water penetration enhancer at certain ratios. In this 
process, the porous and plastic particles are separated by water-penetration-enhancing 
particles, which prevent formation of a viscous layer on the tablet surface. The binder here 
can also secure the porous material and water penetration enhancer during granulation. 
These two components can be easily segregated during mixing without the binder. If the 
binder is in the liquid or semi-solid state, it should not significantly destroy the porous 
structure of the porous materials. One way of achieving this is to use aqueous binder 
solutions with very low water activity. The highly plastic granule approach produces 
FDTs with excellent hardness and fast disintegration time ranging from several seconds to 
about 30 seconds, depending on the size of the tablets. 
 
 
 
 
 
Table No. l.2 Examples of commercially available, preapproval, or submitted orally 
disintegrating tablet products 
Technology Brand name 
Active 
ingredient 
Company Application 
Zydis® 
Claritin® RediTabs® Loratadine 
Schering 
Corporation 
Zydis® 
Antihistamine 
Feldene Melt® Piroxicam Pfi zer NSAID 
Maxalt®-MLT® 
Rizatritpan 
benzoate 
Merck Migrane 
Zyprexa® Olanzapine Eli Lilly Psychotic disorders 
Zofran® ODT® Ondansetron Glaxo Smith Kline Anti-emetic 
Quicksolv® 
Propulsid® 
Quicksolv® 
Cisapride 
monohydrate 
Janssen 
Gastrointestinal 
prokinetic agent 
OraSolv 
Tempra Quicklets 
Tempra FirsTabs 
 
Acetaminophen 
Bristol-Myers 
Squibb 
Analgesic 
DuraSolv® 
 
Alavert® Loratadine 
Wyeth Consumer 
Healthcare 
Allergy 
NuLev® 
Hyoscyamine 
sulfate 
Schwarz Pharma Anti-ulcer 
WOWTAB® 
Benadryl® Fastmelt® 
Diphenhydramine 
citrate 
Pfi zer 
Allergy ,sinus 
pressure relief 
Nasea OD Ramosetoron HCl Yamanouchi Anti-emetic 
QuickTabs™ Excedrin® QuickTabs Acetaminophen 
Bristol-Myers 
Squibb 
Pain reliever 
FlashDose® 
Ralivia FlashDose® Tramadol HCl Biovail Analgesics 
Zolpidem ODT Zolpidem tartrate Biovail Sleep disorders 
Flashtab® Nurofen® Flashtab® Ibuprofen Boots Healthcare NSAID 
OraQuick 
Hyoscyamine Sulfate 
ODT 
Hyoscyamine 
sulfate 
ETHEX 
Corporation 
Anti-ulcer 
Ziplets™ Cibalginadue FAST Ibuprofen 
Novartis Consumer 
Health 
NSAID 
 
 
 
1.5. DETERMINATION OF DISINTEGRATION TIME OF FDT  
FDTs should be strong enough to survive rough handling during manufacturing 
and shipping processes, and yet friable enough to instantly dissolve or disintegrate into 
small particles for easy swallowing by the patient. Conventional disintegration tests for 
ordinary tablets may not allow precise measurement of the disintegration time of FDTs 
because of their fast disintegration. It is also hard to distinguish among FDTs, which 
release their ingredients very quickly. In vitro testing may not always reflect the real in 
vivo disintegration of tablets. In general, the method described in the US Pharmacopoeia 
can produce data for evaluation of the disintegration time; however, no additional 
information might be extracted. It is also possible to evaluate the tendency of the 
disintegration kinetics by visual examination. However, these evaluations are not 
sufficiently objective. When developing FDT formulations, it is important to evaluate the 
effect of different excipients on the disintegration time. In order to predict the 
disintegration time of FDTs and the effects of different formulation parameters, a few 
methods have been proposed. It is important to define a suitable method to better 
distinguish between the disintegration times of different FDTs and to find better 
correlation between in vitro and in vivo data. To achieve this goal, a modified dissolution 
apparatus was applied to FDTs with disintegration times too fast to distinguish the 
differences between the tablets when the conventional methods were used.  
1.5.1. In-Vivo determination of disintegration time:  
In-vivo disintegration tests of FDTs can be conducted on volunteers who are 
usually randomized to receive the treatments and then directed to clean their mouths with 
water. Tablets are placed on their tongues, and the time for disintegration is measured by 
immediately starting a stopwatch. The volunteers are allowed to move FDTs against the 
upper roof of the mouth with their tongue and to cause a gentle tumbling action on the 
tablet without biting on it or tumbling it from side to side. 
Immediately after the last noticeable granule has disintegrated, the stopwatch is 
stopped and the time recorded. 
 
 
1.5.1. In-Vitro determination of disintegration time: 
i) Modified US pharmacopoeia method: 
Instead of using the disintegration apparatus described in the US Pharmacopoeia, a 
modified method has been proposed. The disintegration apparatus was the same as the 
USP dissolution test Apparatus 2, which uses a paddle stirring element and 1000-mL 
cylindrical vessel at 37 °C. Distilled water was chosen for the disintegration medium 
instead of a buffer solution. A tablet to be tested was put on the bottom of a sinker, which 
was placed in the middle of the vessel and hung by a hook to the lid of the vessel with a 
distance of 6–8.5 cm. Disintegration time was determined at the point at which the tablet 
disintegrated and passed through the screen of the sinker completely. The opening of 
mesh of the sinker was 3–3.5 mm in height and 3.5–4 mm in width. 
ii) Texture analyzer method: 
The Texture Analyzer (Stable Micro Systems, U.K.) was applied to measure the 
beginning and ending time of disintegration. A tablet was adhered to the bottom of a 
probe, which was attached to the load cell with a very thin layer of glue or double-sided 
tape. A small amount of water, usually 0.4 ml, in a beaker or petri dish was used as a 
disintegration medium at room temperature. The tablet was submerged in water and 
compressed against the bottom of the beaker or petri dish with a constant pressure. The 
beaker size could be varied, and the beaker could even be a water bath to keep the 
temperature constant. The instrument was programmed to apply a moderate force for up to 
60 seconds so that the penetration distance could be measured as the tablet was 
compressed while submerged in the water. The probe distance would be steady as the 
tablet remained cohesive. However, as the tablet disintegrated, the compression distances 
increased, because the probe had to keep the pressure constant. The time for the tablet to 
disintegrate was determined by measuring the distance the probe travelled into the tablet. 
Typical time-distance profiles generated by the Texture Analyzer software enabled the 
calculation of beginning and ending of disintegration time. 
El-Arini and Clas performed the in vitro disintegration test of commercially 
available FDTs by the Texture Analyzer instrument. The differences in the disintegration 
mechanisms of the FDTs, which derived from the formulation and/or manufacturing 
process, were reflected in the shape of their disintegration profiles. Moreover, the in vitro 
disintegration times obtained by the simulated in vivo conditions were correlated with the 
reported in vivo disintegration times. 
3. CCD camera method: 
The CCD camera apparatus comprises two distinct sections—a disintegration 
component and a measurement device. The mode of measurement involves the continuous 
acquisition of pictures by the CCD camera to record the time course of disintegration. The 
acquired pictures are simultaneously transferred to the computer and stored. The key point 
of this apparatus is to combine the detailed pictures obtained by the CCD camera. 
The disintegration apparatus consists of a plastic cell partitioned into two parts: 
one component comprises an inner tank containing a stirring bar, a grid fabricated from 
stainless-steel, and a disintegration medium (distilled water, 200 ml, 37 ± 2 °C); the 
second component is an outer tank of thermostated water. The grid is constructed of three 
hollow areas equidistant from the centre. These hollow points represent the position of the 
tablets, and a support is added for each tablet to avoid movement during the disintegration 
test. 
The CCD camera method permits documentation of the disintegration time course 
with sequentially obtained pictures. The computer enables calculation of the surface area 
of each tablet at any time point, as well as the design of graphs that show decrease in the 
tablet surface area as a function of time. The disintegration time and the area under the 
curve can be calculated from these graphs as qualitative parameters that can be correlated 
to the oral disintegration time. Consequently, results depend on the direction and focal 
length of the camera relative to the tablet. The disadvantage of the method involves 
difficulty associated with the application of mechanical stress to test tablets. Thus, the 
time required for a single test is several minutes, which is greater than that for the in vivo 
disintegration time.  
4. Rotary-shaft method:  
FDTs generally receive some mechanical stress produced by the tongue in the 
human mouth. Narazaki et al. developed a suitable disintegration method for FDTs. In this 
method, the FDT is placed on stainless steel wire gauze, which is slightly immersed in test 
medium, and a rotary shaft is employed to provide mechanical stress to the tablet by 
means of its rotation and weight. The critical parameters of this method are the rotation 
speed and the mechanical stress. To assess our method, several placebo FDTs were 
prepared and exposed to severe storage conditions (60 °C/75% RH for 1 week) in order to 
obtain FDTs with a wide range of disintegration times. These placebo FDTs were used to 
compare the disintegration times obtained by several methods. The disintegration time of 
the placebo FDTs in human sensory test varied widely after storage. The disintegration 
times determined by the conventional disintegration test were in good correlation to those 
in the human sensory test, but the slope was 0.241, far from 1. There was no correlation 
between the disintegration time of FDTs in the human sensory test and those determined 
by the conventional dissolution test. In contrast, a good correlation between the 
disintegration times was obtained and the slope was 0.858, very close to 1. It was 
concluded that this method was suitable for the measurement of the disintegration time of 
FDTs. This new method might provide a valuable approach for establishing the official 
disintegration test for FDTs in the future. 
5. Sieve method: 
A simple device based on a shaking water bath was designed to measure the 
disintegration time of FDTs. The device is composed of a 10-mesh sieve and a glass 
cylinder. The sieve is placed into the cylinder at a certain position so that 2 ml of 
disintegration medium fills the space below the sieve of the cylinder. Then, 1 ml of the 
medium is added into the device, so that it is available for an FDT to be tested. The device 
is in a reciprocal shaking water bath keeping the temperature at 37 °C. While the shaker is 
running in horizontal back-and-forth motions with 150 rpm, an FDT is placed onto the top 
of the sieve immersed in the disintegration medium. The FDT starts disintegration into 
small particles and/or dissolves. The time at which the particles of the tablet go through 
the sieve completely is determined as the disintegration time. The disintegration time is 
measured using a stopwatch, and this quick method gives reproducible data that are highly 
useful in screening various formulations and testing many formulation variables.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. LITERATURE REVIEW 
2.1 REVIEW OF FDT 
 
  Lokesha Puttalingaiah et al., (2011)
8
 reviewed that oral route is the most 
preferred route for administration of various drugs because it is regarded as safest, most 
convenient and economical route. Fast disintegrating tablets are solid dosage forms which 
dissolve rapidly in saliva without chewing and additional water, overcome the 
disadvantages of conventional dosage form especially dysphagia (difficulty in 
swallowing) in paediatric and geriatric patients. FDT have received ever-increasing 
demand during the last decade, and the field has become a rapidly growing area in the 
pharmaceutical industry. Upon introduction into the mouth, these tablets dissolve or 
disintegrate in the mouth in the absence of additional water for easy administration of 
active pharmaceutical ingredients. The popularity and usefulness of the formulation 
resulted in development of several fast disintegrating tablets technologies. 
 
Rakesh Pahwa et al., (2010) 
9 
studied the importance of Orally Disintegrating 
Tablets which is an alternative to conventional tablet and capsule formulations to obviate 
the problem of dysphagia and to improve patient compliance. In pediatrics and geriatrics 
ODTs have gained considerable attention as preferred, these techniques render the 
disintegration of tablet rapidly and dissolve in mouth without chewing or additional water 
intake.  
 
Tejvir Kaur et al., (2010) 
10 
aimed to design dosage forms, convenient to be 
manufactured and administered, free of side effects, offering immediate release and 
enhanced bioavailability, so as to achieve better patient compliance. Though oral drug 
delivery systems, preferably, tablets are the most widely accepted dosage forms, for being 
compact, offering uniform dose and painless delivery. Yet, dysphagia is the most common 
disadvantage of conventional tablets. This is seen to afflict nearly 35% of the general 
population and associated with a number of conditions, like parkinsonism, mental 
disability, motion sickness, unconsciousness, unavailability of water etc. To overcome 
such problems, certain innovative drug delivery systems, like ‗Mouth Dissolving Tablets‘ 
(MDT) have been developed. These are novel dosage forms which dissolve in saliva 
within a few seconds, when put on tongue. Such MDTs can be administered anywhere and 
anytime, without the need of water and are thus quite suitable for children, elderly and 
mentally disabled patients. 
 
Sharma Shailesh et al., (2010) 
11
 studied Fast Dissolving Drug Delivery System 
emerged from the desire to provide patient with conventional mean of taking their 
medication. Difficulty in swallowing (Dysphagia) is a common problem of all age groups, 
especially elderly and pediatrics, because of physiological changes associated with these 
groups of patients. Solid dosage forms that can be disintegrated, dissolved, or suspended 
by saliva in the mouth resulting in easy swallowing can provide significant benefits to the 
pediatric and geriatric population, as well as other patients who prefer the convenience of 
easily swallowable dosage forms. The FDT has remarkable disintegration properties; 
without water, it is rapidly disintegrated in the mouth within only a few seconds. When 
the FDT is placed in the oral cavity, saliva quickly penetrates into the tablet causing rapid 
disintegration. One of the most important characteristics of the FDT is its disintegration 
time in the oral cavity; however, a suitable method to access the disintegration properties 
described in the official books has not been developed. It is difficult to assess the 
disintegration rate for the FDT with these tests due to its rapid disintegration rate even in a 
small amount of water. To overcome this problem, several new methods have been 
proposed.  
 
Debjit Bhowmik et al., (2009)
12
 reviewed that Fast dissolving Tablets are 
disintegrating and/or dissolve rapidly in the saliva without the need for water. Some 
tablets are designed to dissolve in saliva remarkably fast, within a few seconds, and are 
true fast-dissolving tablets. Fast- or mouth dissolving tablets have been formulated for 
pediatric, geriatric, and bedridden patients and for active patients who are busy and 
traveling and may not have access to water. In some cases such as motion sickness, 
sudden episodes of allergic attack or coughing, and an unavailability of water, swallowing 
conventional tablets may be difficult. 
 
Bhupendra G. Prajapati et al., (2009) 
13
 reviewed recent patents on Fast 
Dissolving Drug Delivery System. A schizophrenic patient in the institutional setting can 
hide a conventional tablet under his or her tongue to avoid their daily dose of an atypical 
antipsychotic. A middle-aged woman undergoing radiation therapy for breast cancer may 
be too nauseous to swallow her H2-blocker. Fast-dissolving/disintegrating tablets 
(FDDTs) are a perfect fit for all of these patients. FDDTs disintegrate and/or dissolve 
rapidly in the saliva without the need for water. Some tablets are designed to dissolve in 
saliva remarkably fast, within a few seconds, and are true fast-dissolving tablets. Others 
contain agents to enhance the rate of tablet disintegration in the oral cavity, and are more 
appropriately termed fast disintegrating tablets, as they may take up to a minute to 
completely disintegrate. 
 
Simone Schiermeier et al., (2002) 
14
 formulated fast dispersible tablets which 
disintegrated either rapidly in water to form a stabilized suspension or disperse 
instantaneously in the mouth to be swallowed without the aid of water. They employed a 
rotatable central composite design to predict the effects of the quantitative factors, 
mannitol and crosspovidone as well as compression force on the characteristics of the 
tablet. 
 
2.2 REVIEW OF DRUG AND SUPER DISINTEGRANTS 
 
Panati Dinakar et al., (2010) 
15
 aimed to investigate the formulation of bisoprolol 
fumarate transdermal patches by using Poly vinyl pyrrolidone (PVP), polyvinyl alcohol 
(PVA) using glycerin as plasticizer for controlled release medication in order to treat the 
blood pressure and cardiac diseases. Studies disclosed that Bisoprolol is more effective 
than Propanolol, Atenolol and Metoprolol. After optimizing the polymer ratio the best 
patches were selected based on the physical evaluation. Then physical evaluation and in 
vitro studies were performed by using Franz diffusion cell employing porcine ear skin as 
the membrane. From the above results F2 formulation was found to have good controlled 
release over the formulation F1. Further in order to find the effect of plasticizer in the 
drug release for the F2 formulation, glycerin was replaced with Tri ethyl citrate (TEC). 
Thus the prepared film shows good release of about 98.3% with TEC as plasticizer. 
 
Sudhir Bhardwaj et al., (2010)
 16 
formulated and evaluated the fast dissolving 
tablet of aceclofenac (anti-inflammatory and analgesic) which was selected as the model 
drug. The poor aqueous solubility of the drug results in variable dissolution rate and hence 
poor bioavailability.  It was concluded that the fast dissolving tablets of the poor soluble 
drug can be made by direct compression technique using selective super disintegrates 
showing enhanced dissolution, taste masking and hence better patient compliance and 
effective therapy. 
 
 
R. Margret Chandira et al., (2010) 
17
 formulated and evaluated mouth dissolving 
tablets of the etoricoxib which is a new non-steroidal anti-inflammatory drug (NSAID). In 
the present investigation variety of super disintegrants like primogel, kollidone, ac-di-sol, 
l-HPMC and l-HPC were selected and tablets were prepared by direct compression 
method in different concentration like 4% and 8%. The main criteria for mouth dissolving 
tablets are to disintegrate or dissolve rapidly in oral cavity with saliva in 15sec to 60sec 
with need of water. The disintegrants used in study fulfills the criteria by disintegrating 
the tablets in specified time limit. 
 
H. A. Patel et al., (2010) 
18
 studied the in-vitro evaluation of fast dissolving tablets 
of domperidone, the formulations containing croscarmellose sodium, cross povidone, and 
sodium starch glycolate as superdisintegrants, disintegrated faster as compared to the 
formulation containing microcrystalline cellulose and In-vitro drug release showed that 
almost drug was released in the range of 94-97% in 10 minutes. It also concludes that 
direct compression method is better than wet granulation method 
 
Indhumathi D. et al., (2010) 
19
 studied the design and optimization of 
orodissolving tablet of antidepressant drug by superdisintegrants addition method. Mouth 
dissolving tablet offers a solution for pediatrics, geriatrics; psychiatric or mentally ill 
people and those have difficulty in swallowing tablets/capsules resulting in improved 
patient compliance. In-vitro dissolution studies showed the release is in the following 
order of superdisintegrants: crospovidone > pregelatinized starch > croscarmellose > 
sodium starch glycolate. Maximum in-vitro dissolution was found to be with formulation 
f-7 and crospovidone (4%) conformed to be best by in-vivo pharmacokinetic studies 
 
A. Prameela Rani et al., (2010) 
20
 formulated and evaluated orodispersible 
metformin tablets and carried out comparative study on isphagula husk and crosspovidone 
as superdisintegrants. In the present study an attempt has been made to prepare fast 
disintegrating tablets of Met.Hcl in the oral cavity with enhanced dissolution rate. The 
tablets were prepared with Isphagula husk, natural superdisintegrant and Crosspovidone, 
synthetic superdisintegrant. The pure drug and formulation blend was examined for angle 
of repose, bulk density, tapped density, Compressibility index and Haussner‘s ratio. The 
tablets were evaluated for hardness, tensile strength, drug content, friability and were 
found satisfactory. The disintegration time in the oral cavity was also tested and was 
found to be around 10sec. Based on dissolution rate the disintegrants can be rated as 
Isphagula husk > Crosspovidone. Hence Ishagula husk was recommended as suitable 
disintegrant for the preparation of direct compression melt‐in‐mouth tablets of Met.Hcl. 
All the dissolution parameters were calculated and compared with market tablet. A 3.78 
fold increase in the dissolution rate was observed with F4 formulation when compared to 
market tablet (Glucophage). It was concluded that the rapidly disintegrating tablets with 
proper hardness, rapid disintegration in the oral cavity with enhanced dissolution rate can 
be made using super disintegrants (natural and synthetic). 
 
Mahaveer P. Khinchi et al., (2010) 
21
 formulated orally disintegrating tablets of 
salbutamol sulphate by employing direct compression technique using directly 
compressible mannitol (pearlitol SD 200), micro crystalline cellulose (MCC), various 
concentration of super disintegrating agents like Ac-di-sol, Primojel, and Polyplasdone R- 
XL as 2%, 3%, 4%, and 5%. These formulations were evaluated for thickness, friability, 
weight uniformity, disintegration time, wetting time, and in-vitro dissolution study. All 
the Formulations has showed satisfactory the result i.e. disintegration was less than one 
minute and in-vitro release was within three minute thus ensure the immediate effect. The 
formulation A-4 and A-8 prepared by Ac-di-sol 5% and Polyplasdone R- XL 5% showed 
100% drug release within two minute and three minute respectively while 100% drug 
release of marketed conventional tablet was found to be within twenty five minute which 
was much higher as compared to mouth dissolving tablet. 
 
Suhas M. Kakade et al., (2010) 
22
 designed mouth dissolving tablets of losartan 
potassium with a view to enhance the patient compliance and provide a quick onset of 
action. The main objective of the study was to formulate mouth dissolving tablets of 
losartan potassium to achieve a better dissolution rate and further improving the 
bioavailability of the drug and were prepared by direct compression and using super 
disintegrants like Polyplasdone XL 10, Croscarmellose sodium and Explotab in different 
concentration and evaluated for the pre-compression parameters such as bulk density, 
compressibility, angle of repose etc. The prepared batches of tablets were evaluated for 
hardness, weight variation, friability, drug con-tent, disintegration time and in-vitro 
dissolution profile and found satisfactory. Among all, the formulation F3 containing 
5%w/w superdisintegrant Polyplasdone XL 10 was considered to be best formulation, 
which release up to 99.26% in 12 min. 
 
Yamsani Madhusudan Rao et al., (2010) 
23
 reported that formulated Bilayer 
tablets provided immediate release of glimepiride and metformin HCl as sustained release 
over a period of 8 hours.The immediate release layer was prepared using sodium starch 
glycolate as super disintegrant and sustained release using HPMC K4M and sodium 
carboxy methyl cellulose as polymers and PVP K30 as binder. Formulations containing 
higher concentration of sodium starch glycolate and SCMC in IR and SR layer 
respectively were optimised for bilayer tablets. 
 
Raghavendra et al., (2009) 
24
 formulated fast dissolving tablet of poorly soluble 
drug carbamazepine by direct compression technique with β cyclodextrin complexes using 
various superdisintegrants such as crosscarmellose sodium, crospovidone, sodium starch 
glycholate, Indion 414. Carbamazepine is used to control different types of seizers in 
treatment of epilepsy. Poor solubility in biological fluids and poor bioavailability after 
oral administration is major problem with this drug. Hence to enhance solubility of drug 
complex with  β cyclodextrin is prepared and compressed in to tablets. Different 
formulations showed disintegration time between 26.86 to58.54 sec. all formulations 
showed release of 99.89% within 4 min. 
 
Venkatesh et al., (2009) 
25
 formulated Oro-dispersible tablets of anti emetic drug 
Ondansetron hydrochloride, it is a very bitter drug and slightly soluble in water. An 
attempt was made to mask the taste and to formulate into a dispersible tablet by 
complexation with ion exchange resins, Cationic exchange resins like Indion-204, Indion-
234 and Tulsion-335 were utilized for the sorption of drug. Drug- resinates were prepared 
in drug to resin ratio of 1:5 and 1:6.The prepared tablets were evaluated for general 
appearance, content uniformity, hardness, friability, taste evaluation, mouth feel, wetting 
time, in-vitro and in-vivo disintegration time, and in-vitro dissolution studies. Dispersion 
not showing any bitter taste, indicate the capability of ion exchange resins used, both as 
taste masking and super disintegrating agents. Almost more than 90% of drug was 
released from the formulations within 1 hour. 
 
B. Jayakar et al., (2009) 
26
 performed design and characterization of fast 
dissolving tablet of telmisartan by using Superdisintegrants–Crospovidone, Ac-de-sol, and 
sodium starch glycolate, level of addition to increase the rate of drug release from dosage 
form to increase the dissolution rate by adding surfactant SLS and hence its 
bioavailability. The Disintegration time of Fast Dissolving tablets were increased by the 
addition of concentration of Superdisintegrants. 
 
Raguia Ali Shoukri et al., (2009) 
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 studied in-vitro and in-vivo evaluation of 
nimesulide lyophilized orally disintegrating tablets development of a lyophilized orally 
disintegrating tablet that enhanced the in vitro dissolution and in vivo absorption of 
nimesulide, a drug with poor solubility and poor bioavailability is presented. 
 
C. P. Jain et al., (2009) 
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 investigated fast dissolving tablets of Valsartan were 
prepared using different superdisintegrants by direct compression method. Wetting time 
of formulations containing Crospovidone was least and tablets showed fastest 
disintegration. The drug release from FDTs increased with increasing concentration of 
superdisintegrants and was found to be highest with formulations containing 
Crospovidone. The release of Valsartan from FDTs was found to follow non-Fickian 
diffusion kinetics. 
 
Narmada G. Y. et al., (2009) 
29
 formulated fast dissolving tablet of amlodipine 
besylate for rapid action. Sublimation method was adapted to prepare the tablets by using 
a 2
3
 full factorial design. FT-IR and D.T.A studies revealed that there was no physico-
chemical interaction between amlodipine besylate and other excipients. All formulations 
are evaluated for pre-compression and post-compression parameters, wetting time, water 
absorption ratio. The results obtained showed that the quantity of starch potato, sodium 
starch glycolate, camphor significantly affect response variables. The results indicate that 
the optimized tablet formulation provides a short DT of 8 sec with sufficient crushing 
strength and acceptable friability. Stability studies of optimized formulation revealed that 
formulation is stable. 
 
P.S. Zade et al., (2009) 
30
 designed to prepare bitterless fast dissolving tablet of 
Tizanidine Hydrochloride using Eudragit E 100 as a taste masking agent. Mass extrusion 
was the technique used for preparing taste masked granules. The tablet was prepared with 
three super disintegrants e.g. sodium starch glycolate, crosscarmellose sodium and 
crospovidone. The blend was examined for angle of repose, bulk density, tapped density 
and hausner‘s ratio. The tablets were evaluated for hardness, drug content and friability 
and disintegration time. The disintegration in oral cavity was also tested and was found to 
be 22 sec. Other tablets were prepared by using camphor as sublimating agent. It was 
concluded that tablets prepared by addition of superdisintegrant has less disintegration 
time than those prepared by sublimation method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. AIM AND OBJECTIVE 
3.1 AIM: 
Bisoprolol Fumarate is a cardioselective β-blocker which is used for the treatment 
of stable chronic heart failure with reduced systolic left ventricular function in addition to 
ACE inhibitors, diuretics, and optionally cardiac glycosides. 
The presently preferred route of administration for Bisoprolol fumarate is oral. The 
oral dosage form is of compressed tablet prepared by direct compression method.  
The rapid onset of action is not achieved through conventional dosage form. To 
overcome this problem fast dissolving drug delivery system was choosen. 
The main aim of the present work is to formulate ‗Fast Dissolving Tablet‘ of 
Bisoprolol Fumarate by using various super disintegrants like Croscarmellose sodium, 
SSG, Crosspovidone, PVP K-30. 
 
3.2 OBJECTIVES 
 To provide a drug delivery system which provides rapid onset of action. 
 To provide a drug delivery system which increases the patient compliance, 
effectiveness of therapy and reduces the chance of adverse effects. 
 To develop a physicochemical stable drug delivery system of Bisoprolol fumarate  
 To evaluate all the parameters of formulation in detail. 
 To optimize the parameters using factorial design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. PLAN OF WORK 
The present work was carried out to prepare and evaluate Fast Dissolving drug 
delivery system of Bisoprolol Fumarate with different superdisintegrants in various 
concentrations. The following experimental protocol was therefore designed to allow a 
systemic approach to the study. 
1. Preformulation studies 
a) Identification and Characterization of Bisoprolol Fumarate 
 Melting point determination 
 FTIR spectroscopy 
b) Preparation of standard calibration curve in pH 1.2 
c) Compatibility studies of drug & excipients by FTIR 
2. Evaluation of Pre Compression parameters 
a) Angle of repose 
b) Bulk density 
c) Tapped density 
d) Carr‘s index 
e) Hausner‘s ratio 
3. Formulation of Fast dissolving tablets of Bisoprolol Fumarate 
4. Evaluation of Post Compression parameters 
a) Thickness 
b) Hardness 
c) Weight variation 
d) Friability 
e) Wetting time 
f) Disintegration time 
g) Drug content 
h) In- vitro drug release study 
i) Stability studies 
5. Statistical optimization of parameters by 32 full factorial design 
 
 
 
 
 
5. DRUG PROFILE 
5.1 BISOPROLOL FUMARATE 
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: 
Chemical Formula: C18 H31 N O4 ½ C4H4O4 
Chemical Structure:  
OH
NH
H3C CH3
O
O
OH3C
CH3
CH
HC
O
OH
O
OH
 
IUPAC Name: (±) -1- [[a- (2-isopropoxyethoxy)-p-tolyl]oxy]-3- (isopropylamino)-
2-propanol fumarate 
  
Brand Names: Concor, Zebeta, Concore, Monocor 
Drug Category:        Selective β1 adrenergic receptor blocker  
Molecular Weight:    766.97 
CAS number: 66722-44-9 
State:                          Solid 
Taste:   bitter less 
Appearance:  It is a white crystalline powder 
Melting Point:            101
o
C 
Solubility:   readily soluble in water, methanol, ethanol, and chloroform. 
Indication:                  For the treatment of hypertension 
Dose:                           Minimum 1.25mg to Maximum 10mg/day 
Bioavailability:          >90%           
 Pharmacology: 
Bisoprolol has both lipid and water soluble properties making it a prime candidate 
over other β-blockers and even over other β1-blockers, being water soluble it will have 
decreased incidence of central nervous system side effects (inability to diffuse into brain) 
compared to purely lipophilic compounds. Bisoprolol has an approximate half-life of 10-
12 hours and when ingested has nearly complete absorption into the blood stream. The 
high absorption is indicative of high bioavailability (approx. 90%). When being 
eliminated, the body evenly distributes it (50-50) between kidney excretion and liver 
biotransformation (then excreted). These factors make it a convenient once/day dosage 
when it‘s being administered. 
 Bisoprolol beta 1-selectivity is especially important in comparison to other non-
selective beta blockers. The effects of the drug are limited to areas containing β1 
adrenoreceptors which is mainly the heart and a little bit of the kidney. Bisoprolol 
minimizes the side effects that might occur from administration of a non-specific beta 
blocker where blockage of the other adrenoreceptors (β2, β3, α1, α2) occurs. The other 
receptors elicit a variety of responses in the body and blockage of them could cause a 
wide range of reactions; but β1 adrenoreceptors are cardio specific for the most part, 
making Bisoprolol ideal for treatment of cardiac events. Bisoprolol has a higher degree of 
β1-selectivity compared to other β1-selective β-blockers such as atenolol, metoprolol and 
betaxolol. 
Mechanism of Action: 
            Bisoprolol is cardioprotective because it selectively and competitively blocks 
catecholamine (adrenalin) stimulation of beta-1 adrenergic receptors (β1 adrenoreceptor) 
mainly found in the heart muscle cells and heart conduction tissue (cardio specific) but 
also found in juxtaglomerular cells in the kidney. Normally adrenalin and noradrenalin 
stimulation of the β1 adrenoreceptor activates a signalling cascade (Gs protein and cAMP) 
which ultimately lead to increased contractility and increased heart rate of the heart 
muscle and heart pacemaker respectively. Bisoprolol competitively blocks the activation 
of this cascade and therefore decreases the adrenergic tone/stimulation of the heart muscle 
and pacemaker cells. Decreased adrenergic tone shows less contractility of heart muscle 
and lowered heart rate of heart pacemaker. 
These are the favourable factors that are decreased and treat hypertension, heart 
attacks and ischemia. The decreases in contractility and heart rate are beneficial for 
hypertension because they reduce blood pressure but for preventive measures for heart 
attacks and cardiac ischemia these decreases in heart rate and contraction decrease the 
hearts demand for oxygen and nutrients; primary treatment post heart attacks is to prevent 
recurrence of the infarction. 
Absorption:            
Bisoprolol fumarate is almost totally (> 90%) absorbed after oral administration. 
On its first passage through the liver (first-pass effect) a maximum of 10% of the dose is 
inactivated by metabolisation. 
The high absorption rate and small first-pass effect result in an absolute 
bioavailability of 88%. Bisoprolol fumarate can be taken on an empty stomach or with 
breakfast 
Protein Binding:  
            Plasma protein binding is about ~30% 
Biotransformation: 
Minimally metabolized by conjugation to form a pharmacologically inactive 
acylglucuronide; the glucuronide of the parent compound is the only metabolite that has 
been identified in human plasma and urine. The cytochrome P450 isoenzymes are not 
involved in the metabolism of telmisartan. 
Half Life: Elimination half-life: 10 –12 h 
 
 
 
 
 
 
 
 
 
 
6. EXCIPIENTS PROFILE 
6.1 CROSCARMELLOSE SODIUM 
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:  
Chemical Formula:  [(C6H10O5) Na
+
] n     n~220 
Chemical Structure: 
O
O
O
OH
OH
OH
OH
OH
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HO
O
H
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CAS number  : 74811-65-7   
Synonyms  : Ac-Di-Sol; Cross linked carboxymethylcellulose sodium;  
                                      explocel; modified cellulose gum; primellose; solutab.  
Chemical name          : Cellulose, carboxymethyl ether, sodium salt, cross linked.   
Nonproprietary name: BP: Croscarmellose sodium. 
                                        PhEur: Carmellosumnatricumconexum. 
                                        USPNF: Croscarmellose sodium.  
Functional category    : Tablet and capsule disintegrant. 
Molecular weight         : 90000 – 700000 
Melting point               : brown at 227
0
C, chars at 252
o
C 
Description    : as an odorless, white or grayish White Powder. 
Solubility                     :   Insoluble in water, but rapidly swells 4 to 8 times it‘s  
     Original volume on contact with water.  
 
 
Application: Croscarmellose sodium is used in oral pharmaceutical formulation as                                            
a disintegrant for capsules, tablets, and granules.  
In tablet formulations, Croscarmellose sodium may be used in both direct 
compression and wet granulation processes. When used in wet granulations, the 
Croscarmellose sodium should be added in both the wet and dry stages of the process 
(intra and extra granularly) so that the wicking and swelling ability of the disintegrant is 
best utilized. Croscarmellose sodium at concentrations up to 15% w/w may be used as a 
tablet disintegrants.  
Stability and storage conditions: 
Croscarmellose sodium is a stable though hygroscopic material. A modal tablet 
formulation prepared by direct compression, with Croscarmellose sodium as a 
disintegrant, showed no significant difference in drug dissolution after storage at 30 
0
C for 
14 months. Croscarmellose sodium should be stored in a well-closed container in a cool, 
dry place. 
 
6.2 SODIUM STARCH GLYCOLATE 
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: 
Chemical Formula:  (C26H44O17Na)n      
Chemical Structure: 
O O
CH2O
OH
OH OH
OH
CH2OH
O
OH
OH
CH2OH
* O
CH2COONa
O O *
n  
CAS number  : 9063-38-1 
Synonyms  : Carboxymethyl starch, sodium salt, explotab, primojel,  
vivastar p. 
Chemical name:  Sodium carboxymethyl starch. 
Nonproprietary names:   BP: Sodium starch glycolate. 
                              PhEur:  Carboxymethylamylumnatricum. 
                              USPNF: Sodium starch glycolate. 
Functional category:   Tablet and capsule disintegrant.  
Molecular weight:      500000-1000000 
Melting point:  Does not melt, but chars at approximately 200
o
C 
Description:   Sodium starch glycolate is a white to off-white, odour,  
tasteless, free flowing powder. It consist of oval or  
spherical granules 30-100µm in diameter. 
Swelling capacity:      In water, sodium starch glycolate swell up to 300 times in  
volume. 
Solubility: 
Sparingly soluble in ethanol (95%), practically insoluble in water. At a 
concentration of 2% w/v sodium starch glycolate disperses in cold water and settles in the 
form of a highly hydrated layer. It swells up to 300 times of its volume in water.  
Applications: 
Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsule and tablet formulations. It is commonly used in tablets prepared by either by 
direct compression    or wet granulation processes. The usual concentration employed in 
the formulation is between 2 % and 8 %, with the optimum concentration about  4 % 
,although in cases 2% is sufficient. Disintegration occurs by rapid uptake of water 
followed by rapid and enormous swelling.  
Storage and stability: 
Tablets prepared with sodium starch glycolate have good storage properties. 
Sodium starch glycolate is stable and should be stored in a well closed container in order 
to protect it from wide variations of humidity and temperature, which may cause caking. 
Its physical properties remain unchanged up to four years if it stored in moderate 
temperature and humidity.     
Regulatory status: 
Included in the FDA inactive ingredients guide (oral capsule and tablets) included 
in nonparental medication licensed in the UK 
 
6.3 CROSSPOVIDONE 
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: 
Chemical Formula:  (C6H9NO) n      
Chemical Structure: 
 
Synonym:                      PVP, Povidone, PolyvidonePoly [1-(2-oxo-1-pyrrolidinyl) 
ethylene] 1- 
                                       Ethenyl-2-pyrrolidon homopolymer 1-Vinyl-2-pyrrolidinon-
Polymere 
                                       Copovidone PNVP 
CAS number:    9003-39-8 
Molecular formula:     (C6H9NO) n 
Molar mass:                  2.500 - 2.5000.000 
 
Appearance:                 white to light yellow, hygroscopic, amorphous powder 
Density:                         1, 2 g/cm³ 
Melting point:              110 - 180 °C (glass temperature) 
Solubility:                 Completely insoluble in water, acids, alkalis, and all organic  
      solvents. Hygroscopic. Swells rapidly in water. Rapidly disperses  
in water, but Does not gel even after prolonged exposure 
Physical Characteristics: pH (10% slurry): 5.0 – 8.0 Moisture (Karl-Fisher): £ 5.0%  
 
Uses: 
1. Medical 
            The polymer PVP was used as a blood plasma expander for trauma victims after 
the first half of the 20th century. It is used as a binder in many pharmaceutical tablets; it 
simply passes through the body when taken orally. However, autopsies have found that 
crospovidone does contribute to pulmonary vascular injury in substance abusers who have 
injected pharmaceutical tablets intended for oral consumption. The long-term effects of 
crospovidone within the lung are unknown. PVP added to iodine forms a complex called 
povidone-iodine that possesses disinfectant properties. This complex is used in various 
products like solutions, ointment, pessaries, liquid soaps and surgical scrubs. It is known 
for instance under the trade name Betadine. 
2. Technical 
          PVP is also used in many technical applications: 
 As adhesive in glue stick and hot melts 
 As special additive for batteries, ceramics, fibreglass, inks, inkjet paper and in the 
chemical-mechanical planarization process 
 As emulsifier and disintegrant for solution polymerization 
 As photoresist for cathode ray tubes (CRT) 
 use in aqueous metal quenching 
 for production of membranes, such as dialysis and water purification filters 
 As a binder and complexation agent in agro applications such as crop protection, 
seed treatment and coating 
 As a thickening agent in tooth whitening gels 
 As an aid for increasing the solubility of drugs in liquid and semi-liquid dosage 
forms (syrups, soft gelatine capsules) and as an inhibitor of recrystallisation 
 As an additive to Doro's RNA extraction buffer 
3. Other uses 
PVP is also used in personal care products, such as shampoos and toothpastes, in 
paints, and adhesives that must be moistened, such as old-style postage stamps and 
envelopes. It has also been used in contact lens solutions and in steel-quenching solutions. 
PVP is the basis of the early formulas for hair sprays and hair gels, and still continues to 
be a component of some. As a food additive, PVP is a stabilizer and has E number E1201. 
PVPP is E1202. It is also used in the wine industry as a fining agent for white wine. Other 
references state that polyvinyl pyrrolidone and its derivatives are fully from mineral 
synthetic origin. Therefore, its use in the production should not be a problem for vegans. 
In molecular biology, PVP can be used as a blocking agent during Southern blot 
analysis as a component of Denhardt's buffer. It is also exceptionally good at absorbing 
polyphenols during DNA purification. Polyphenols are common in many plant tissues and 
can deactivate proteins if not removed and therefore inhibit many downstream reactions 
like PCR. 
Safety: 
The USFDA has approved this chemical for many uses and it is generally 
considered safe. However, there have been documented cases of allergic reactions to 
PVP/povidone, particularly regarding subcutaneous (applied under the skin) use and 
situations where the PVP has come in contact with autologous serum (internal blood 
fluids) and mucous membranes. For example, a boy having an anaphylactic response after 
application of PVP-I (PVP-Iodine) for treatment of impetigo was found to be allergic to 
the PVP component of the solution. A woman, who had previously experienced urticaria 
(hives) from various hair products, later found to contain PVP, had an anaphylactic 
response after povidone-iodine solution was applied internally. She was found to be 
allergic to PVP. In another case, a man experiencing anaphylaxis after taking 
acetaminophen tablets orally was found to be allergic to PVP.  
Povidone is commonly used in conjunction with other chemicals. Some of these, 
such as iodine, are blamed for allergic responses, although testing results in some patients 
show no signs of allergy to the suspect chemical. Allergies attributed to these other 
chemicals may possibly be caused by the PVP instead. 
 
 
 
 
6.4 PVP K-30 
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: 
Nonproprietary Names:  BP: Povidone 
JP: Povidone 
PhEur: Povidonum 
USP: Povidone 
Synonyms:  E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-
yrrolidinyl)ethylene]; polyvidone; polyvinylpyrrolidone; 
PVP; 1-vinyl-2-pyrrolidinone polymer. 
Chemical Name:   1-Ethenyl-2-pyrrolidinone homopolymer  
Chemical Formula:   (C6H9NO) n  
Molecular Weight:  2500–3 000 000 
Structural Formula: 
 
CAS number:    9003-39-8 
Functional Category: Disintegrant; dissolution aid; suspending agent; tablet binder. 
Applications in Pharmaceutical Formulation or Technology 
Although povidone is used in a variety of pharmaceutical formulations, it is 
primarily used in solid-dosage forms. In tableting, povidone solutions are used as binders 
in wet-granulation processes. Povidone is also added to powder blends in the dry form and 
granulated in situ by the addition of water, alcohol, or hydroalcoholic solutions. Povidone 
is used as a solubilizer in oral and parenteral formulations and has been shown to enhance 
dissolution of poorly soluble drugs from solid-dosage forms. Povidone solutions may also 
be used as coating agents. 
Povidone is additionally used as a suspending, stabilizing, or viscosity-increasing 
agent in a number of topical and oral suspensions and solutions. The solubility of a 
number of poorly soluble active drugs may be increased by mixing with povidone. 
 
 
 
 
Uses of PVP K-30: 
Table No. 6.1 Uses of PVP K-30 
Use Concentration (%) 
Carrier for drug 10-25 
Dispersing agent Up to 5 
Eye drops 2-10 
Suspending agent Up to 5 
Tablet binder, tablet diluent, or coating agent 0.5-5 
 
Special grades of pyrogen-free povidone are available and have been used in 
parenteral formulations 
Description:  
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30 are 
manufactured by spray-drying and occur as spheres. Povidone K-90 and higher K-value 
povidones are manufactured by drum drying and occur as plates. 
Typical Properties: 
Acidity/alkalinity:  pH = 3.0–7.0 (5% w/v aqueous solution). 
Density (bulk):  0.29–0.39 g/cm3 for Plasdone. 
Density (tapped):  0.39–0.54 g/cm3  
Density (true):  1.180 g/cm
3
 
Flowability:   16 g/s  
Melting point:  softens at 150°C. 
 
Solubility:   
Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and water; 
practically insoluble in ether, hydrocarbons, and mineral oil. In water, the concentration of 
a solution is limited only by the viscosity of the resulting solution, which is a function of 
the K-value. 
Viscosity (dynamic):  
the viscosity of aqueous povidone solutions depends on both the concentration and the 
molecular weight of the polymer employed. 
 
6.5 MICROCRYSTALLINE CELLULOSE (MCC) 
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: 
Synonyms                     :          Avicel, cellulose gel, emocel, fibrocel, tabulose, vivacel 
Chemical name            :         Cellulose 
CAS number    : 9000-11-7  
Chemical formula   :         (C6H10O5) 
Molecular weight        :         36,000 
Non proprietary name:       BP Microcrystalline cellulose 
                                                 PhEur: Cellulosum microcrystalline cellulose 
                                                 USPNF: microcrystalline cellulose 
Melting point               :          Chars at 260-270
O
C 
Nominal mean particle size:   100µm 
Specific surface area   :          1.21-1.30m
2
/g 
Description: 
Microcrystalline cellulose is purified partially depolymerized cellulose that occurs 
as a white colored, odourless crystalline powder composed of porous particles. It is 
commercially available at different size grades, which have different properties and 
applications. 
Property of some commercially available grade of microcrystalline cellulose: 
Table No. 6.2 Grade of microcrystalline cellulose 
Grade  Nominal mean partical 
size (µm) 
Moisture content (%) 
Avicel PH 101                   50                  ≤ 5.0 
Avicel PH 102                  100                  ≤ 5.0 
Avicel PH 103                   50                  ≤ 3.0 
Avicel PH 105                   20                  ≤ 5.0 
Avicel PH 112                  100                  ≤ 1.5 
Avicel PH 113                   50                  ≤ 1.5 
Avicel PH 200                  180                  ≤ 5.0 
Avicel PH 301                   50                  ≤ 5.0 
Avicel PH 302                  100                  ≤ 5.0 
 
Pharmaceutical application of MCC: 
Table No. 6.3 Pharmaceutical application of MCC 
USE  Concentration (%) 
Adsorbent  20-90 
Anti-adherent 5-20 
Capsule diluents 20-90 
Tablets disintegrant 5-15 
Tablet binder/ Diluents 20-90 
 
Application:   
Microcrystalline cellulose is widely used in pharmaceuticals primarily as diluents 
in oral tablet and capsule formulations, where it is used in both wet granulation and direct 
compression processes..in addition to use as diluents, MCC also has some lubricant and 
disintegrant properties that make it useful in tableting. It is used as tablet disintegrant in 5-
20% concentration, while as diluents 20-29% concentration is employed. 
 
6.6 MANNITOL 
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: 
Chemical name:          hexanitro mannitol 
HO
HO OH
HO OH
HO
mannitol  
Synonym:                     mannitol hexanitrate, nitromannite, nitromannitol, nitranitol, 
mannitrin 
IUPAC:                        (2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol-1,2,3,4,5,6-hexanitrate 
CAS number:    69-65-8 
Molecular formula:      C6H8N6O18 
Molar mass:                      452.15712 
Density:                               1.604 g/cc 
Melting point:               112 °C = 234 °F 
Mol. mass:                     182.172 
Bioavailability: 
In pharmacology, bioavailability is used to describe the fraction of an 
administered dose of unchanged drug that reaches the systemic circulation, one of the 
principal pharmacokinetic properties of drugs. By definition, when a medication is 
administered intravenously, its bioavailability is 100%. However, when a medication is 
administered via other routes (such as orally), its bioavailability decreases (due to 
incomplete absorption and first-pass metabolism) or may vary from patient to patient (due 
to inter-individual variation).             Bioavailability is one of the essential tools in 
Pharmacokinetics, as bioavailability must be considered when calculating dosages for 
non-intravenous routes of administration. 
For dietary supplements, herbs and other nutrients in which the route of 
administration is nearly always oral, bioavailability generally designates simply the 
quantity or fraction of the ingested dose that is absorbed. Bioavailability is defined 
slightly differently for drugs as opposed to dietary supplements primarily due to the 
method of administration and Food and Drug Administration regulations. 
Use: This polyol is used as an osmotic diuretic agent and a weak renal vasodilator 
Mannitol is also the first drug of choice for the treatment of acute glaucoma in veterinary 
medicine. It is administered as a 20% solution IV. It dehydrates the vitreous humor and, 
thus, lowers the intraocular pressure. However, it requires an intact blood-ocular barrier to 
work. Mannitol can also be used to temporarily encapsulate a sharp object (such as a helix 
on a lead for an artificial pacemaker) while it is passed through the venous system. 
Because the mannitol dissolves readily in blood, the sharp point will become exposed at 
its destination. 
Mannitol may be administered in cases of severe Ciguatera poisoning. Severe 
ciguatoxin, or "tropical fish poisoning" can produce stroke-like symptoms. Mannitol is the 
primary ingredient of Mannitol Salt Agar, a bacterial growth medium, and is used in 
others. In oral doses larger than 20 g, mannitol acts as an osmotic laxative, and is 
sometimes sold as a laxative for children 
Toxicology: Mannitol is contraindicated in patients with anuria and Congestive Heart 
Failure 
 
6.7 MAGNESIUM STEARATE 
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: 
Non-proprietary name: BP: Magnesium stearate 
                                        PhEur: Magnesiistearas 
                                        USPNF: Magnesium stearate 
Synonyms:                     E 572, Hyqual, Magnesium salt. 
Chemical name:            Octadecanoic acid Magnesium Salt. 
CAS number:     557-04-0 
Empirical Formula:      C36H70MgO4 
Molecular Formula:      591.27 
Functional category:     Tablet and capsule lubricant 
Flowability:                    Poorly flowing, cohesive powder 
Melting point:                88.5
o
C 
Moisture content:          3.85% 
Solubility:                       Practically insoluble in ethanol, ethanol 95%, ether and water ; 
     slightly soluble in warm benzene and warm ethanol 95%. 
Description:   
Magnesium stearate is a fine, white, precipitated or milled, implantable powder of 
low bulk density having a faint, characteristic odour and taste, the powder is greasy to 
touch and readily adheres to the skin. 
Polymerisation: 
A trihydrate, acicular from and a dehydrate lamellar form have been isolated with 
the latter processing the better lubricating properties. 
Stability and storage condition: 
Magnesium stearate is stable and should be stored in a well-closed container in a 
cool and dry place. 
Incompatibilities: 
Incompatible with strong acid, alkalis and iron salts. Avoid mixing with strong 
oxidizing material. 
Safety:  
Magnesium stearate is used as a pharmaceutical excipients and is generally 
regarded as being nontoxic following oral administration. However oral consumption of 
large quantities may result in some laxative effect or mucosal irritation. Inhalation of 
magnesium stearate powder is harmful and has resulted in fatalities. 
Handling precaution:  
Observe normal precaution appropriate to the circumstances and quantity of 
material handled. Eye protection and glove are recommended 
 
6.8 TALC 
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:  
Synonyms –  
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; Magsil Star; 
powdered talc; purified French chalk; Purtalc; soapstone; steatite; Superiore. 
 
Chemical Name:  Talc 
CAS number:  14807-96-6 
Empirical Formula:  Mg6 (Si2O5)4(OH)4 
Functional Category: Anticaking agent; glidant; tablet and capsule diluent; tablet 
and capsule lubricant. 
 
Applications in Pharmaceutical Formulation: 
Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent, although today it is less commonly used. However, it is widely used as a 
dissolution retardant in the development of controlled-release products. Talc is also used 
as a lubricant in tablet formulations; in a novel powder coating for extended-release 
pellets; and as an adsorbant. In topical preparations, talc is used as a dusting powder, 
although it should not be used to dust surgical gloves. 
 
Use:  Dusting powder (90.0–99.0%) 
           Glidant and tablet lubricant (1.0–10.0%) 
           Tablet and capsule diluent (5.0–30.0%) 
 
Description: Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch 
and free from grittiness. 
 
Solubility: practically insoluble in dilute acids and alkalis, organic solvents, and water 
. 
Specific gravity:  2.7–2.8. 
 
Specific surface area: 2.41–2.42m2/gm. 
 
Stability and Storage Conditions - Talc is a stable material and may be sterilized by 
heating at 160
0
C for not less than 1 hour. It may also be sterilized by exposure to ethylene 
oxide or gamma irradiation. Talc should be stored in a well-closed container in a cool, dry 
place. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. MATERIALS AND INSTRUMENTS 
7.1 MATERIALS USED FOR THE RESEARCH WORK 
Table No. 7.1 Materials used for the research work 
 
 
 
 
 
 
 
 
 
 
 
 
7.2 INSTRUMENTS USED FOR THE RESEARCH WORK 
Table No.7.2 Instruments used for the research work 
Sr.No Name Grade Company 
1 Bisoprolol Fumarate Pharma Merck Ltd.,Aurangabad 
2 Hydrochloric acid AR Loba Chem Pvt. Ltd., Mumbai. 
3 Potassium hydroxide AR Loba Chem Pvt. Ltd., Mumbai. 
4 Potassium di-hydrogen phosphate AR S.D.Fine Chem Ltd., Mumbai. 
5 Sodium hydroxide AR Loba Chem Pvt. Ltd., Mumbai. 
6 Di. Sodium hydrogen phosphate AR Loba Chem Pvt. Ltd., Mumbai. 
7 Deionized water AR Leo Scientific, Erode. 
8 Lactose AR Loba Chem Pvt. Ltd., Mumbai. 
9 Microcrystalline cellulose AR Loba Chem Pvt. Ltd., Mumbai. 
10 Sod. Starch Glycolete AR Loba Chem Pvt. Ltd., Mumbai. 
11 Cross Povidone AR Loba Chem Pvt. Ltd., Mumbai. 
12 PVP K-30 AR Loba Chem Pvt. Ltd., Mumbai. 
13 Crosscarmellose sodium AR Loba Chem Pvt. Ltd., Mumbai. 
14 Mannitol AR Loba Chem Pvt. Ltd., Mumbai. 
S. No. Instruments Manufacturer 
1 
Rotary Press Tablet 
Compression Machine 
RIMEK Minipress-I, 
Karnavati Engineering Ltd., 
Mehsana, Gujarat. 
2 Electronic Balance 
Dhona Instruments Pvt. Ltd., 
Kolkata. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 Digital pH meter 
Model No. NIG 333, 
Naina Solaris Ltd. India. 
4 Monsanto Hardness tester 
Cadmach Machinery Pvt. Ltd., 
Ahmedabad. 
5 Roche Friabilator USP XVIII 
Model No. EF-1W, 
Electrolab Pvt. Ltd., Goregaon (E), 
Mumbai. 
6 Sieves Sethi Standard Test Sieves 
7 
Double Beam  
UV-Spectrophotometer 
Techcomp UV 2300 
8 Dissolution Apparatus USP XVIII 
Model No. TDT – 06P, 
Electrolab Pvt. Ltd., Goregaon (E), 
Mumbai. 
9 FTIR Spectrophotometer 
Model No. 8400 S, 
Shimadzu Asia Pacific Pvt. Ltd., 
Singapore. 
10 Digital Vernier Caliper ASAHI, India. 
11 Ultrasonicator PCI, Mumbai. 
12 Magnetic stirrer 
Model No. 1MLH,  
Remi, Mumbai 
13 Design expert 8.0.7.1 
Stat-Ease, Inc. 
Minneapolis 
8. METHODOLOGY 
8.1 PREFORMULATION STUDIES: 
8.1.1 Identification and Characterization of Bisoprolol Fumarate 
i) Melting point:  
The melting point of Bisoprolol Fumarate was determined by capillary method and 
checked, whether it complies with the reported ones or not.  
ii) FT-IR spectroscopy 
(40, 41)
: 
Bisoprolol Fumarate was dried in hot air oven at 50
0
C for 2 hours. The samples 
were mixed with potassium bromide (KBr) in ratio 1:100 by using mortar and pestle. This 
physical mixture was compressed under pressure of 10 Ton/nm
2
 and converted in a 
circular disc. This disc was then placed in the scanning slot of Fourier Transform Infra-red 
(FT-IR) Spectrophotometer and scanned at range from 400 to 4000 cm
-1 
to obtain the 
FTIR of Bisoprolol Fumarate 
8.1.2 Preparation of standard curve in pH 1.2 
42
: 
Accurately weighed 100 mg of Bisoprolol Fumarate was dissolved in 100 ml of 
distilled water. The solution was suitably diluted to prepare solutions of strengths ranging 
from 1 to 10 µg / ml with 0.1 N HCl. These solutions were scanned by UV 
spectrophotometer at 220 nm and the calibration curve was plotted. 
The reagents were prepared as per IP. 
i. Preparation of 0.1M hydrochloric acid (HCl) solution: Conc. HCl diluted with 
distilled water so that final solution contains 3.646 g of hydrochloric acid in 1000.0 ml 
to obtain 0.1M hydrochloric acid solution. 
 
ii. Preparation of 0.2M hydrochloric acid (HCl) solution: Conc. HCl diluted with 
distilled water so that final solution contains 7.292 g of hydrochloric acid in 1000.0 ml 
to obtain 0.2M hydrochloric acid solution. 
 
iii. Preparation of 0.2M potassium chloride (KCl) solution: Dissolve approx. 14.911 g 
of potassium chloride in distilled water and diluted to 1000.0 ml with distilled water to 
obtain 0.2M potassium chloride solution. 
 
iv. Preparation of dilution media (pH 1.2 hydrochloric acid buffer): About 250.0 ml 
of 0.2M potassium chloride solution was placed in a 1000.0 ml volumetric flask. To 
this, about 425.0 ml of 0.2M hydrochloric acid was added and then volume was 
adjusted to 1000 ml with distilled water. Then prepared solution was tested using pH 
meter. The pH of solution was adjusted to pH 1.2 with the help of 0.2M hydrochloric 
acid. 
8.1.3 Compatibility studies of drug & excipients by FT-IR: 
             IR spectra of drug and all super disintegrants long with drug  in KBr pellets at 
moderate scanning speed between 4000-400cm
-1
 was carried out using FTIR. The peak 
values and the possibility of functional groups shown in spectra were compared with 
standard values. 
 
8.2 EVALUATION OF PRE COMPRESSION PARAMETERS 
(43, 44)
: 
 
 8.2.1 Angle of repose 
Angle of repose was determined by using fixed funnel method. It is the maximum 
angle that can be obtained between the free flowing surface of lubricated blend of matrix 
tablets heap and the horizontal plane. Accurately weighed lubricated blends were allowed 
to fall freely through a funnel until apex of conical pile just touched the tip of the funnel. 
The angle of repose θ was determined according to the following formula: 
θ = tan-1 (h/r) 
Where,  
h = height of the pile 
r = radius of the pile 
θ = angle of repose 
8.2.2 Bulk density  
  Ten grams of drug and excipients mixture (powder) was placed into 100 ml 
measuring cylinder and volume was noted. The bulk density was calculated by the 
following equation 
                                        ρo = M/Vb 
 Where, 
 ρo =bulk density, 
 M =mass of the powder and 
 Vb= Volume of powder 
8.2.3 Tapped density  
  10 gm of drug and excipients mixture (powder) was taken in measuring cylinder. 
The cylinder was then subjected to a fixed number of taps (100). The final volume was 
recorded and the tap density was calculated by the following equation 
                                           ρt =M/V 
Where, ρt=tapped density, 
M= mass of the powder and 
Vt =Volume of powder on tapping. 
8.2.4 Compressibility index 
Compressibility of the drug was determined using the following equation                  
 % compressibility= (ρt- ρo/ ρt) 100 
Where, 
 ρt is the tapped density and 
 ρo is the bulk density. 
 
 
8.2.5 Hausner’s ratio  
A similar index has been defined by Hausner 
Tapped Density 
Hauser‘s ratio = 
  Bulk density 
  It indicates that the flow properties of the powder and is measured by the ratio of 
tapped density to bulk density. 
Value less than 1.25 (= 25% Carr‘s index) indicates good flow while greater than 
1.25 indicate poor flow (= 33% Carr‘s index). Between 1.25 and 1.5 added Glidants 
normally improves flow. 
 
8.3 FORMULATION OF FAST DISSOLVING TABLETS: 
Bisoprolol Fumarate fast dissolving tablets were prepared by direct compression 
method. A total number of twelve formulations were prepared. All the ingredients were 
passed through 60-mesh sieve separately and collected, finally compressed into tablets 
after lubrication with magnesium stearate (2%) and talc (2%) by using 9/32 mm concave 
punch using RIMEK 8 station tablet compression machine. 
 
 
 
 
 
 
 
Table No. 8.1 Formulation of blend 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Bisoprolol fumarate 5 5 5 5 5 5 5 5 5 5 5 5 
Crosspovidone 2 4 6 - - - - - - - - - 
Croscarmilose sodium - - - 2 4 6 - - - - - - 
SSG - - - - - - 2 4 6 - - - 
PVP K-30 - - - - - - - - - 2 4 6 
Mannitol 55 55 55 55 55 55 55 55 55 55 55 55 
MCC 26 24 22 26 24 22 26 24 22 26 24 22 
Lactose 8 8 8 8 8 8 8 8 8 8 8 8 
Mag. Stearate 2 2 2 2 2 2 2 2 2 2 2 2 
Talc 2 2 2 2 2 2 2 2 2 2 2 2 
*each tablet weight 100 mg 
 
8.4 EVALUATION OF POST COMPRESSION PARAMETERS 
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: 
 
8.4.1 Thickness 
The thickness of the tablets was determined using a digital vernier calliper 
(ASAHI, India). Five tablets from each batch were used and average values were 
calculated. 
8.4.2 Hardness  
Hardness of the tablets has been defined as the force required for breaking a tablet 
in diametric compression. The resistance of the tablets to chipping, abrasion or breakage 
under the conditions of storage, transportation and handling before usage depends in its 
hardness.  For each formulation, the hardness of 3 tablets was determined using the 
Monsanto hardness tester. The tablet was held along its oblong axis in between the two 
jaws of the tester. At this point, reading should be zero kg/cm2. Then constant force was 
applied by rotating the knob until the tablet fractured. The value at this point was noted in 
kg/cm2. 
8.4.3 Weight variation  
Twenty tablets were selected randomly and average weight was determined. Then 
individual tablets were weighed and was compared with average weight. 
Table No. 8.2 Weight variation limits 
Average weight of Tablets (mg.) Maximum percentage deviation 
 
130 or less 
 
130 – 324 
 
324 mg or more 
 
10 
 
7.5 
 
5 
 
Not more than two of the individual weights deviate from the average weight by 
more than the percentage shown in above table and none deviates by more than twice of 
that percentage. 
8.4.4 Friability  
Friability was measured to find the strength of tablet by Roche Friabilator. This 
test subjects a number of tablets to the combined effect of shock abrasion by utilizing a 
plastic chamber which revolves at a speed of 25 rpm, dropping the tablets to a distance of 
6 inches in each revolution. A sample of preweighed 10 tablets was placed in Roche 
friabilator which was then operated for 100 revolutions i.e. 4 minutes. The tablets were 
then dusted and reweighed. A loss of less than 1 % in weight is generally considered 
acceptable. Percent friability was calculated as follows, 
 
     Percentage friability =     (Initial weight – Final weight / Initial weigh)   x 100 
                                                                         
 
 
8.4.5 Wetting time 
 A piece of tissue paper folded double was placed in a Petri dish containing 6 ml of 
water .the tablet was placed on the paper, and the time for complete wetting of the tablet 
was measured in seconds. The method was slightly modified by maintaining water at 
37
0
c.Wetting time corresponding to the time taken for the tablet to disintegrate when kept 
motionless on the Petri dish. 
8.4.6 Disintegration time  
Disintegration time was determined using USP tablet disintegration test apparatus 
using 900ml of distilled water without disk at room temperature (30
0
C). If 1 or 2 tablets 
fail to disintegrate completely, repeat the test on additional 12 numbers. Not less than 16 
of the total of 18 numbers tested disintegrate completely. 
8.4.7 Drug content 
The drug content was determined by eluting the crushed tablet with continuous 
stirring in 100 ml 1N HCl for 4 hour to ensure complete elution. The solution was filtered. 
After suitable dilution the drug content was determined at 220 nm by UV/VIS 
spectrophotometer. According to USP acceptable limit is ± 10%. 
Calculation:        
                             spl abs       std wt           1          100            100           avg wt          
Amount of BF= --------X-- ------- X -------- X---------- X ---------- X------------- X potency 
                              Std abs       100           100       spl wt            1               100   
 
8.4.8 In-vitro Dissolution Study  
Dissolution profiles of Bisoprolol Fumarate fast dissolving tablets were 
determined using the USP 24 Method II with paddle speed 50 rpm. Dissolution was 
performed in 900 ml of 0.1N HCl maintained at 37 ± 0.5°C. 5 ml of samples were 
withdrawn at specified time intervals. The volume of dissolution fluid was adjusted to 900 
ml, by replacing each 5 ml aliquot withdrawn with 5 ml of 0.1N Hcl, pre-warmed at 37± 
0.5°C. Samples withdrawn were filtered through whatmann filter paper, suitably diluted 
with 0.1N HCl and analyzed at 220 nm. 
 
8.4.9 Stability studies 
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Stability of a formulation can be defined as the time from date on manufacture of 
the formulation until its chemical or biological activity is not less than a pre-determined 
level of labelled potency and its physical characteristic have not changed appreciably or 
deleteriously. 
Formulation and the development of a pharmaceutical product are not complete 
without proper stability analysis, carried out on it to assess the physical and chemical 
stability and the safety. The purpose of stability testing is to provide evidence on how the 
quality of a drug substance or drug product varies with time under the influence of a 
variety of environment factor such as temperature, humidity and light enabling 
recommended storage condition, re-test periods and shelf lives. 
Generally the observation of the rate at which the product degrades under normal 
room temperature requires a long time. To avoid the undesirable delay, the principle of 
accelerated stability studies is adopted. 
The international conference on harmonization (ICH) guideline titled ―stability 
testing of new drug substance and product‖ (QIA) describes the stability test requirements 
for drug registrations application in the European Union, Japan and United States of 
America. ICH specifies the length of study and storage conditions.  
 Long term testing: 250c ± 20c/60% RH ± 5% for 12 months. 
 Accelerated testing: 400c ± 20c/ 75 % RH ± 5% for 6 months. 
 
Method: 
The selected formulation were packed in tightly closed container were plugged 
with cotton and capped. they were then stored at 40
0
c  ± 2
0
c/ 75 % RH  ± 5% for 3 months 
in humidity chamber (Thermolab Mumbai) and valuate for their physical appearance and 
drug solution were further scanned to observe any possible spectral changes T80% was 
calculated by using dissolution studies. 
 
8.5 STATISTICAL OPTIMIZATION OF PARAMETERS BY FACTORIAL 
DESIGN 
29,
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: 
It is desirable to develop an acceptable pharmaceutical formulation in shortest 
possible time using minimum number of man-hours and raw materials. Traditionally 
pharmaceutical formulations after developed by changing one variable at a time approach. 
It is therefore very essential to understand the complexity of pharmaceutical formulations 
by using established statistical tools such as factorial design. In addition to the art of 
formulation, the technique of factorial design is an effective method of indicating the 
relative significance of a number of variables and their interactions. A statistical model 
incorporating interactive and polynomial terms was used to evaluate the responses. The 
number of experiments required for these studies is dependent on the number of 
independent variables selected. The response (Yi) is measured for each trial. 
Y=β0+β1X1+β2X2+β3X1X2+β4X1
2+β5X2
2+β6X1
2
X2+β7X1X2
2+β8X1
2
X2
2
 
           Where, Y is the dependent variable, 
                         X1, X2 are independent variables, 
                         b0 is the arithmetic mean response of the nine runs and 
                         bi is the estimated coefficient for the factor Xi. 
The main effects (X1 and X2) represent the average result of changing one factor at a time 
from its low to high value. The interaction terms (X1X2) show how the response changes 
when two factors are simultaneously changed. A 3
2
 randomized full factorial design was 
utilized in the present study. In this design two factors were evaluated, each at three 
levels, and experimental trials were carried out at all nine possible combinations. The 
factors were selected based on preliminary study. The concentration of lactose (X1) and 
concentration of Magnesium stearate (X2) were selected as independent variables. % 
friability, wetting time, disintegration time and in-vitro drug release was respectively 
selected as dependent variables were tested for significance by using Design Expert 
8.0.7.1  
9. RESULTS AND DISCUSSION 
  The present work was aimed to find out the effects of various superdisintegrants 
on the dissolution profile, In-vitro release Kinetic studies and various properties of oral 
dispersible tablets of Bisoprolol Fumarate. 
9.1 PREFORMULATION STUDIES: 
9.1.1 Identification and Characterization of Bisoprolol Fumarate:  
i) Melting point 
The melting point of Bisoprolol Fumarate was determined by capillary method and 
was found to be 101 ºC. It complies with the standards as given in USP. 
 
ii) Identification test for Bisoprolol Fumarate. 
Infrared absorption spectrophotometry: All the prominent and primary peaks were 
observed in FTIR spectrum of Bisoprolol Fumarate. (Fig. 9.1) and match with the 
reference spectrum. 
Table No. 9.1 FT-IR interpretation of bisoprolol fumarate 
 
Group Range Std. peak 
C-H bending 
(alkynes) 
600-700 663.53 
N-H Wagging, 
(Amines) 
655-910 805.31 
C-O stretching, 
(alcohol) 
1045-1055 1049.75, 
C-N stretching, 
(amine) 
1030-1230 1091.75, 1123.57 
C-O stretching, 
(carboxylic acid) 
1000-1320 1236.41, 1235.45 
C-H rocking, 
(alkynes) 
1350-1370 1365.65 
C=C stretching, 
(alkenes) 
1606-1616 1615.44 
-CH3 (alkanes) 2865-2875 2867.28 
 
 
 
 
 
 
  
 
Fig No. 9.1 FTIR Spectrum of drug sample 
9.1.2 Standard calibration curve of bisoprolol fumarate in buffer pH 1.2: 
i) Preparation of standard calibration curve in HCl buffer pH 1.2:  
Standard calibration curve was prepared for concentration of 1µg/ml to 10µg/ml at 
220 nm. The graph of concentration v/s absorbance was plotted and data were subjected to 
linear regression analysis. The data of absorbance is as shown in Table No. 9.2. The data 
had correlation coefficient of 0.997 and equation of regressed line is, y=0.101X-0.035 
 
Table No. 9.2 Absorbance values for standard calibration curve of Bisoprolol 
Fumarate in hydrochloric acid buffer pH 1.2 
Sr. no. Concentration (μg/ml) Absorbance 
1 
1 0.069 
2 
2 0.166 
3 
3 0.241 
4 
4 0.349 
5 
5 0.457 
6 
6 0.583 
7 
7 0.697 
8 
8 0.785 
9 
9 0.881 
10 
10 0.992 
 
 Fig. No.9.2 Standard calibration curve of Bisoprolol Fumarate in pH 1.2 buffer 
The calibration curve for Bisoprolol Fumarate in pH 1.2 buffers in the 
concentration range of 1μg/ml to 10μg/ml was a straight line. The absorbance increased 
with the increase in concentration. Thus the standard curve followed the Beer-Lambert‘s 
Law. 
9.1.3 Organoleptic characteristics: 
                           Table No.9.3 Organoleptic characteristics of Pure Drug 
Sr.no Properties Results 
1 Colour White 
2 Odour Odour less 
3 Taste Bitter less 
4 Appearance Amorphous powder 
 
9.1.4 Drug and Excipients compatibility studies: 
Infrared spectra matching approach was used for the detection of any possible 
chemical reaction between the drug and Excipients. About 1 mg of this mixture was 
mixed with 100 mg of potassium bromide (KBr) and compressed to from a transparent 
pellet using a hydraulic press at 10 tons pressure. It was scanned from 4000 to400cm-1 in 
a Perkin Elmer FT-IR Spectrophotometer.  The IR spectrum of the physical mixture 
was done to detect any appearance or disappearance of peaks. The compatibility between 
the drug and to selected super disintegrants was evaluated using FTIR matching method.  
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Table No. 9.4 Drug and excipients compatibility 
Group Range 
FT-IR of pure 
drug 
FT-IR of physical 
mixture 
C-H bending 
(alkynes) 
600-700 663.53 662.57 
N-H Wagging, 
(Amines) 
655-910 805.31 805.31, 835.31, 835.21 
C-O stretching, 
(alcohol) 
1045-1055 1049.75, 1050.28 
C-N stretching, 
(amine) 
1030-1230 1091.75, 1123.57 1091.75, 1123.57 
C-O stretching, 
(carboxylic acid) 
1000-1320 1236.41, 1235.45 1235.45, 1236.41 
C-H rocking, 
(alkynes) 
1350-1370 1365.65 1363.72, 1364.68 
C=C stretching, 
(alkenes) 
1606-1616 1615.44 1614.47, 1613.51 
-CH3 (alkanes) 2865-2875 2867.28 2866, 2867.28 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Fig. No. 9.3 FT-IR Spectrum of Drug with Ac-di-sol 
 
 
 
                       
Fig. No. 9.4 FT-IR Spectrum of Drug with sodium starch glycolate 
 
  
 
                              
Fig. No. 9.5 FT-IR Spectrum of Drug with Crospovidone 
 
 
 
  
Fig. No. 9.6 FT-IR Spectrum of Drug with PVP K-30 
 
 
9.2 PRECOMPRESSION STUDY OF TABLET BLEND: 
Twelve formulations were prepared by using 2%, 4%, 6% concentration of 
superdisintegration like croscarmellose sodium (Ac-di-Sol), sodium starch glycolate, 
Crospovidone and PVP K-30. For each designed formulation, powder mixed blend of 
drug and excipients was prepared and evaluated for various parameters as follows. 
Table No. 9.5 Comparison of Pre compression parameters 
Formulation 
Code 
Formulation parameters 
Angle of 
repose(º) 
Bulk 
density(Kg/cm
2
) 
Tapped 
density(Kg/cm
2
) 
Carr’s 
index 
(%) 
Hausner’s 
ratio 
F1 24.91 0.31 0.36 13.888 1.161 
F2 26.79 0.32 0.37 13.513 1.156 
F3 23.45 0.3 0.34 11.764 1.133 
F4 22 .86 0.33 0.36 8.333 1.090 
F5 25.21 0.31 0.34 8.823 1.096 
F6 22.17 0.33 0.38 13.157 1.151 
F7 23.86 0.32 0.36 11.111 1.125 
F8 26.54 0.3 0.35 14.285 1.166 
F9 28.13 0.31 0.34 8.823 1.096 
F10 25.37 0.33 0.39 15.384 1.181 
F11 26.51 0.34 0.37 8.108 1.088 
F12 29.10 0.32 0.35 8.571 1.093 
 
9.2.1 Angle of Repose (θ): 
The angle of repose of all formulated batches prepared with different 
superdisintegrants and various powder mixed blends, was measured by cylinder method. 
Angle of repose was found in the range from 22º70' to 29º10' this implies excellent free 
flowing nature of blends.  
 
 
9.2.2 Bulk density: 
The bulk density of all formulated batches prepared with different 
superdisintegrants and various powder mixed blends. The bulk density was found in the 
range from 0.53 to 0.54 g/cm
3
 
9.2.3 Tapped density:  
The tapped density of all formulated batches prepared with different 
superdisintegrants and various powder mixed blends, was measured by cylinder method. 
The tapped density was found in the range from 0.602 to 0.627 g/cm
3
 
9.2.4 Compressibility Index: 
The compressibility index of all formulated batches prepared with different 
superdisintegrants and various powder mixed blends by using bulk density and tapped 
density data, compressibility index was calculated. It was found in the range 11.48 % to 
15.89 %  
9.2.5 Hausner ratio: 
The Hausner ratio of all formulated batches prepared with different 
superdisintegrants and various powder mixed blends was calculated by using bulk density 
and tapped density data. It was found in the range of 1.12 to 1.20.  
 
 
 
 
 
 
 
 
 
9.3 FORMULATION OF FDT: 
 
 
 
 Fig. No. 9.7 Formulated tablet 
 
 
 
 
 
 
 
9.4 COMPARITIVE STUDIES OF POST-COMPRESSION PARAMETERS: 
The research works was carried out to analysis and study the impact of various 
superdisintegrants on enhancing the dissolution rate of Bisoprolol Fumarate. The 
experiment was design with twelve formulations which were categorize into three group 
based on the concentration of three different superdisintegrants. 
Table No. 9.6 comparative study of post compression parameters 
    
Code 
Formulation parameters 
Weight 
variation 
(mg) 
Thickness 
(mm) 
Hardness 
(kg/cm
2
) 
Friability 
(%) 
Disintegration 
time (sec) 
Wetting 
time (sec) 
F1 101 2.5 3.2 0.43 32 57 
F2 103.25 2.5 3.4 0.51 30 54 
F3 99.56 2.6 3.1 0.49 28 56 
F4 100.78 2.4 3.3 0.50 29 57 
F5 101.24 2.7 3.3 0.56 27 55 
F6 100.67 2.5 3.2 0.48 24 54 
F7 104.53 2.3 3.4 0.57 36 59 
F8 98.76 2.7 3.3 0.49 33 57 
F9 99.89 2.6 3.1 0.60 32 56 
F10 100.37 2.4 3.5 0.55 38 60 
F11 102.65 2.5 3.4 0.44 37 58 
F12 100.05 2.3 3.3 0.49 37 57 
 
9.4.1 Weight variation: 
Tablets were prepared using dry granulation technique. Since the material was free 
flowing, tablets were obtained of uniforms weight due to uniform die fill. The tablets were 
obtained in the range with acceptable weight variations as per pharmacopoeia 
specifications less than 7.5%.  
 
 
9.4.2 Thickness uniformity: 
Tablets were evaluated by using vernier caliper. The thickness of tablets was 
found to be exact 2.5 mm uniform thickness was obtained due to uniform die fill.  
9.4.3 Hardness: 
Tablets were evaluated by using hardness tester. Hardness of the tablets was found 
in the range 3.1 to 3.5 Kg/cm
2
 
9.4.4 Friability: 
Tablets were evaluated by using Roche Friabilator and Friability of tablets was 
observed in acceptable range 0.43 to 0.60 (Less than 1%). 
9.4.5 Wetting time: 
A piece of tissue paper folded twice was  placed in a small petri-dish (6.5cm) 
containing 6ml of water, a tablet was placed on the paper and the time for complete 
wetting was measured the wetted tablet was then weighed and the water absorption ratio 
was calculated for each batch. The ratio was calculated for each batch. 
9.4.6 Disintegration time: 
Tablets were evaluated for disintegration time in the disintegration test apparatus 
(I.P). The disintegration time was found in between 24 to 38 sec for all the batches. The 
batch F6 showed the fastest disintegration (24 sec) 
 
 
 
 
 
 
 
 
                  
 
a) At 5 sec                b) At 10 sec 
                    
c) At 15 sec                 d) At 20 sec 
            
  
e) At 25 sec                 f) At 25 sec (side view) 
 
Fig. No. 9.8 Disintegration time of F6 at different time intervals 
 
9.4.7 Drug content: 
Table No. 9.7 Percentage drug content 
S. No. Formulation code % Drug content 
1 F1 98.96 
2 F2 98.99 
3 F3 99.20 
4 F4 99.02 
5 F5 99.37 
6 F6 99.54 
7 F7 98.60 
8 F8 99.08 
9 F9 99.26 
10 F10 99.46 
11 F11 98.92 
12 F12 99.17 
                                                                  
The results for content uniformity are presented in Table No 9.7. The results 
showed drug content were lying within the limits. The assay limit of bisoprolol fumarate 
tablets as per USP is 90-110%. The assays of the tablets were carried out as a process 
given in USP  
9.4.8 In-vitro release studies: 
The Comparative analysis of each formulation was based on in vitro kinetic 
parameters, which elucidated the release profile. The time taken for 80% drug release was 
taken as a response for comparative interpretation of superdisintegrants. The in-vitro 
releases of fast dissolving tablets of Bisoprolol Fumarate for all formulation were given as 
follows. 
In vitro drug release studies details: 
Apparatus used                         : USP XXIII dissolution test apparatus 
Dissolution medium                  : 0.1N HCL  
Dissolution medium volume     : 900 ml 
Temperature                              : 37±0.5ºC 
Speed of basket paddle             : 50 rpm 
Sampling intervals                     : 1 min  
Sample withdrawn                     : 10 ml 
Absorbance measured                : 220 nm 
i) In-vitro release studies of batch F1-F3 in 0.1N HCL 
                  Table No. 9.8 In-vitro release studies of batch F1-F3 in 0.1N HCL 
S. No 
Time 
(min) 
Percentage drug Release 
F1 F2 F3 
1 1 6.06 6.24 6.77 
2 2 12.33 12.87 13.23 
3 3 18.64 19.53 20.07 
4 4 26.76 27.48 30.16 
5 5 32.61 33.51 40.31 
6 6 38.85 40.29 50.69 
7 7 45.83 47.29 60.06 
8 8 52.86 56.28 70.19 
9 9 59.20 64.96 78.95 
10 10 66.12 71.55 83.30 
11 11 73.61 78.53 91.41 
12 12 80.42 85.91 99.03 
13 13 87.09 93.14 - 
14 14 94.69 99.88 - 
15 15 99.83 - - 
 
 
Fig. No. 9.9 In-vitro release studies of batch F1-F3 in 0.1N HCL 
ii) In-vitro release studies of batch F4-F6 in 0.1N HCL 
                   Table No. 9.9 In-vitro release studies of batch F4-F6 in 0.1N HCL 
S. No 
Time 
(min) 
Percentage drug Release 
F4 F5 F6 
1 1 6.59 6.95 7.30 
2 2 12.69 12.87 16.79 
3 3 19.17 19.89 25.44 
4 4 27.48 28.55 35.02 
5 5 31.55 32.81 43.41 
6 6 39.56 41.01 52.21 
7 7 46.73 50.32 63.72 
8 8 52.87 57.55 76.72 
9 9 59.21 66.24 90.15 
10 10 67.56 75.15 99.91 
11 11 75.59 84.83 - 
12 12 85.44 91.88 - 
13 13 92.32 99.86 - 
14 14 99.59 - - 
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 Fig. No. 9.10 In-vitro release studies of batch F4-F6 in 0.1N HCL 
 
 
iii) In-vitro release studies of batch F7-F9 in 0.1N HCL 
                    Table No. 9.10 In-vitro release studies of batch F7-F9 in 0.1N HCL 
S. No 
Time 
(min) 
Percentage drug Release 
F7 F8 F9 
1 1 5.70 6.23 6.95 
2 2 11.97 12.50 14.47 
3 3 19.34 20.06 21.68 
4 4 27.65 28.55 30.17 
5 5 34.57 35.65 39.79 
6 6 40.82 42.62 49.81 
7 7 47.82 49.27 60.06 
8 8 53.07 57.03 72.15 
9 9 59.95 67.14 79.85 
10 10 67.58 78.02 88.49 
11 11 75.08 87.53 93.24 
12 12 82.08 91.04 99.45 
13 13 89.47 99.19 - 
14 14 95.66 - - 
15 15 99.55 - - 
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                     Fig. No. 9.11 In-vitro release studies of batch F7-F9 in 0.1N HCL 
 
iv) In-vitro release studies of batch F10-F12 in 0.1N HCL 
Table No. 9.11 In-vitro release studies of batch F10-F12 in 0.1N HCL 
S. No 
Time 
(min) 
Percentage drug Release 
F10 F11 F12 
1 1 5.34 5.52 6.41 
2 2 11.07 11.61 13.40 
3 3 18.09 20.05 20.78 
4 4 26.74 27.11 28.91 
5 5 33.84 34.92 36.02 
6 6 41.33 42.78 42.99 
7 7 51.54 52.46 52.14 
8 8 58.59 59.88 61.69 
9 9 67.65 67.51 67.91 
10 10 74.25 75.54 76.30 
11 11 80.71 80.76 81.52 
12 12 86.50 84.94 86.42 
13 13 91.06 91.64 93.48 
14 14 95.12 96.05 99.86 
15 15 99.55 99.95 - 
 
0
20
40
60
80
100
120
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
%
  
d
ru
g
 r
el
ea
se
Time (min)
F7
F8
F9
 Fig. No. 9.12 In-vitro release studies of batch F10-F12 in 0.1N HCL 
0
20
40
60
80
100
120
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
%
 d
ru
g
 r
el
ea
se
Time (min)
F10
F11
F12
COMPARATIVE IN-VITRO DRUG RELEASE PROFILE OF FAST DISSOLVING TABLET OF BISOPROLOL FUMARATE IN 
0.1N HCL 
Table No. 9.12 Comparative in-vitro drug release profile 
 
 
 
 
 
 
 
 
 
 
 
Time 
Percent drug release 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
1 6.06 6.24 6.77 6.59 6.95 7.31 5.70 6.24 6.95 5.35 5.52 6.42 
2 12.33 12.87 13.23 12.69 12.87 16.79 11.97 12.51 14.47 11.08 11.61 13.40 
3 18.64 19.53 20.07 19.18 19.89 25.44 19.35 20.06 21.68 18.09 20.06 20.78 
4 26.76 27.48 30.16 27.48 28.56 35.03 27.65 28.55 30.18 26.75 27.12 28.92 
5 32.61 33.51 40.31 31.55 32.81 43.42 34.58 35.66 39.79 33.84 34.93 36.03 
6 38.85 40.29 50.69 39.57 41.01 52.21 40.82 42.63 49.81 41.34 42.79 43.00 
7 45.83 47.29 60.06 46.73 50.33 63.72 47.82 49.28 60.07 51.54 52.47 52.14 
8 52.86 56.28 70.19 52.87 57.55 76.73 53.07 57.03 72.16 58.60 59.88 61.70 
9 59.20 64.96 78.95 59.22 66.24 90.16 59.96 67.14 79.86 67.65 67.51 67.91 
10 66.12 71.55 83.30 67.56 75.16 99.91 67.59 78.02 88.49 74.26 75.55 76.30 
11 73.61 78.53 91.41 75.59 84.83 - 75.08 87.54 93.25 80.72 80.77 81.53 
12 80.42 85.91 99.03 85.44 91.89 - 82.08 91.04 99.45 86.50 84.95 86.43 
13 87.09 93.14 - 92.32 99.87 - 89.48 99.20 - 91.07 91.64 93.49 
14 94.69 99.88 - 99.59 - - 95.66 - - 95.12 96.05 99.87 
15 99.83 - - - - - 99.56 - - 99.55 99.95 - 
                
 
Fig. No. 9.13 Comparative in-vitro drug release profile of Bisoprolol Fumarate FDT 
in 0.1N HCL 
9.4.9 Stability studies 
The optimised FDT were subjected to stability studies and results were tabulated. 
                Table  No. 9.13 Stability study at 40˚C/75% RH     
Parameters 1
st
 month 2
nd
 month 3
rd
 month 
RT 40˚C RT 40˚C RT 40˚C 
Uniformity 
of weight 
passes passes passes passes passes Passes 
Thickness 
(mm) 
2.5±0.09
1 
2.5±0.09
4 
2.5±0.07
3 
0.950±0.0
98 
0.955±0.0
95 
0.951±0.0
89 
Hardness 
(Kg/cm
2
) 
6.74±0.6
93 
6.74±0.6
82 
6.74±0.6
84 
6.74±0.69
7 
6.74±0.69
1 
6.74±0.68
8 
Disintegrati
on time (sec) 
2.77±0.2
61 
2.76±0.2
85 
2.77±0.2
29 
2.77±0.24
9 
2.77±0.23
7 
2.77±0.28
9 
Friability 
(%) 
0.16±0.2
32 
0.16±0.3
25 
0.17±0.2
11 
0.16±0.28
1 
0.16±0.26
1 
0.16±0.24
7 
 
 
9.5 EXPERIMENTAL DESIGN FOR OPTIMIZATION 
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 In the present study a 3
2
 full factorial design was employed. The experimental 
trials were performed at 9 possible combinations and the two independent formulation 
variables evaluated included: 
Table No. 9.14 Selected factor levels for the experimental design for optimization. 
Factor Details Factor Level 
Code Actual Units -1 0 +1 
X1 Lactose mg 6 8 10 
X2 Magnesium Stearate mg 1 2 3 
 
Table No. 9.15 Observations of FDT parameter evaluation for factorial design trials. 
Code Run Independent 
Variables  
Dependent Variables 
  X1 X2 % 
Friability 
Wetting 
time (sec) 
Disintegration 
Time (sec) 
In-vitro 
Release* 
(min) 
7 1 -1 -1 0.81 70 56 98.87 
8 2 0 -1 0.38 58 29 99.91 
9 3 +1 -1 0.59 67 41 99.06 
5 4 -1 0 0.35 45 23 99.92 
3 5 0 0 0.63 59 38 98.99 
1 6 +1 0 0.86 63 59 98.24 
2 7 -1 +1 0.34 54 43 99.26 
4 8 0 +1 0.21 68 57 98.21 
6 9 -1 +1 0.23 74 63 98.04 
*At the end of 10
th
 min 
 
 
 
 
 
9.5.1 Effect of formulation variables on % Friability (R1): 
  Fig. No. 9.14 represents the observed response values compared to that of 
predicted values. The effect of factors A and B can be further elucidated with the help of 
response surface plot Fig. No. 9.15 
 Fig. No. 9.14 Correlation between actual and predicted values for % Friability (R1). 
 
Fig. No. 9.15 Response surface plots showing the effect of Lactose and Mag.Stearate 
(R1). 
 
  The models (R1) were found to be not significant with F value of 0.014 and P 
value of 0.9863. In this case A and B are not significant model terms. The model 
describing the % Friability (R1) can be written as: R1 = +0.53954 -2.37437E-003*A-
0.015680*B. 
 
9.5.2 Effect of formulation variables on Wetting time (R2):  
   Fig. No. 9.16 represents the observed response values compared to that of 
predicted values. The effect of factors A and B can be further elucidated with the help of 
response surface plot Fig. No. 9.17  
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Fig. No. 9.16 Correlation between actual and predicted values for Wetting time (R2). 
 
Fig. No. 9.17 Response surface plots showing the effect of Lactose and Mg. sterate on 
Wetting time (R2). 
 
  The terms R2 of the model were found to be significant with an F value                
of 9.30 and P value of 0.014. In this case A and B are significant model terms.                 
The model describing the Witting time (R2) can be written a:                                            
R2 = +27.84746+3.03293*A+4.94454*B. 
9.5.3 Effect of formulation variables on Disintegration time (R3):  
  Fig. No. 9.18 represents the observed response values compared to that of 
predicted values. The effect of factors A and B can be further elucidated with the help of 
response surface plot Fig. No. 9.19  
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Fig. No. 9.18 Correlation between actual and predicted values for disintegration time 
(R3). 
 
 
Fig. No. 9.19 Response surface plots showing the effect of Lactose and Mg. Sterate on 
disintegration time (R3). 
 
The terms R3 of the model were found to be significant with an F value of 5.36 
and P value of 0.0463. In this case A and B are significant model terms. The model 
describing the disintegration time (R3) can be written as:                                                  
R3 = -4.46115+5.38020*A+3.43198*B. 
9.5.4 Effect of formulation variables on In-vitro Release (R4) 
   Fig. No. 9.20 represents the observed response values compared to that of 
predicted values. The effect of factors A, B and C can be further elucidated with the help 
of response surface plot Fig. No. 9.21  
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Fig. No. 9.20 Correlation between actual and predicted values for In-vitro Release 
(R4). 
 
 
Fig. No. 9.21 Response surface plots showing the effect of Lactose and Mg. sterate on 
In-vitro Release (R4). 
 
  The terms R4 of the model were found to be significant with an F value of 5.68 
and P value of 0.0412. In this case A and B are significant model terms. The model 
describing the In-vitro release (R4) can be written as: R2 = +101.31602-0.27864 * A-
0.071213 * B. 
 
 
 
9.5.5 Analysis of Variance for Dependent Variables from Factorial Design 
Table No. 9.16 Analysis of Variance for Dependent Variables from Factorial Design 
Source Sum square d.f Mean square F value Probability 
% Friability 
 R2=0.0046 
Lactose 1.804E-004 1 1.804E-004 2.318E-003 0.9632 
Mg. stearate 1.967E-003 1 1.967E-003 0.025 0.8789 
Wetting time 
     R2=0.7561 
Lactose 294.36 1 294.36 11.17 0.0156 
Mg. stearate 195.59 1 195.59 7.42 0.0344 
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  A: lactose    B: mg. stearate  
Disintegration time 
     R2=0.6409 
Lactose 926.29 1 926.29 9.72 0.0206 
Mg. stearate 94.23 1 94.23 0.99 0.3584 
In-vitro release studies 
     R2=0.6545 
Lactose 2.48 1 2.48 11.18 0.0155 
Mg. stearate 0.041 1 0.041 0.18 0.6841 
 
 
9.5.6 Optimized formula: 
A numerical optimization technique, focused on the desirability approach, was 
used to generate the optimum settings for the most effective formulation. The objective in 
the design of the process was to optimize the dependent (response) variables R1, R2, R3 
and R4. The optimized formulation was prepared, evaluated for the various responses and 
showed a good relationship between experimental and predicted values, which confirms 
the practicability and validity of the model.  
Table No. 9.17 Comparison between the experimental (E) and predicted (P) values 
for the most probable optimal formulation 
 Dependent variables 
Optimized 
formulation 
% 
Friability 
Wetting time 
(sec) 
Disintegration 
time (sec) 
In-vitro release 
studies (min) 
Predicted (P) 0.59 58 41 98.99 
Experimental (E) 0.48 62 38 99.04 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10. CONCLUSION 
From the present study which was carried out to formulate and optimize the 
parameter of Fast dissolving tablets contain Bisoprolol Fumarate by direct compression 
method; the following conclusion can be drawn. 
           The total weight of F6 batch was 100 mg contained Bisoprolol Fumarate -5%, 
croscarmilose sodium -6%, Mannitol-55%, microcrystalline cellulose 26%, Lactose-8%, 
magnesium stearate- 2%, talc-2%.   
            The Prefromulation study provided the following information of optimized batch 
as Angle of repose- 22º17' good to flow, Bulk density-0.33 g/cm
3
, Tapped density-0.38 
g/cm
3 
, Compressibility Index-11.11 %  good to flow, Hausner‘s ratio-1.125. 
            Post parameter evaluation of tablets were found to be Weight variation-100.67± 
obeys the IP limits ± 7.5 % , Thickness uniformity-2.5 mm, Hardness-3.2 Kg/cm
2
, 
Friability-0.48 %, Wetting time-54, Disintegration time-24 sec, In-vitro release studies- in 
10 min.   
            From the above result it has been concluded that croscarmilose sodium at high 
concentration (6%) given quick disintegration (24 sec) and in-vitro drug release (99.91%) 
in 10 min. Based on disintegration and in-vitro drug release formulation (F6) containing   
croscarmilose sodium (6%) was the optimized batch. 
 
The results of a 3
2
 full factorial design revealed that the amount of lactose and 
magnesium stearate significantly affect the dependent variables such as % friability, 
wetting time, disintegration time and In-vitro drug release. Thus it is concluded that by 
adopting a systematic formulation approach, an optimum point can be reached in the 
shortest time with minimum efforts. 
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